[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3295
1. Stathopoulos GP, Koutantos J, Vaslamatzis MM, Athanasiadis A, Papadopoulos G, Labrodimou G, Stathopoulos J, Rigatos S: Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study. Oncol Rep; 2009 Aug;22(2):345-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study.
  • In the past, it was believed that when advanced-stage prostate cancer became resistant to hormonal management, no chemotherapy should be administered, as survival was not prolonged.
  • Sixty-five patients with advanced prostate cancer were included.
  • The inclusion criteria involved histological confirmation of adenocarcinoma and resistance to hormonal therapy.
  • The hormone treatment preceded the cytotoxic administration and no amelioration in the patients nor prostate serum antigen (PSA) reduction was observed.
  • Patients with hormone-resistant advanced prostate cancer do have good prospects for receiving substantial benefit with the addition of chemotherapy, as observed in the present trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Prostatic Neoplasms / drug therapy


2. Wohlmuth H, Deseo MA, Brushett DJ, Thompson DR, Macfarlane G, Stevenson LM, Leach DN: Diarylheptanoid from Pleuranthodium racemigerum with in vitro prostaglandin E(2) inhibitory and cytotoxic activity. J Nat Prod; 2010 Apr 23;73(4):743-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The compound also demonstrated cytotoxic activity against the P388D1 murine lymphoblast cell line (IC(50) = 117.0 microM) and four human cell lines: Caco-2 colonic adenocarcinoma (IC(50) = 44.8 microM), PC3 prostate adenocarcinoma (IC(50) = 23.6 microM), HepG2 hepatocyte carcinoma (IC(50) = 40.6 microM), and MCF7 mammary adenocarcinoma (IC(50) = 56.9 microM).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20297825.001).
  • [ISSN] 1520-6025
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diarylheptanoids; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


3. Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW, von Schulthess GK, Hany TF: Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology; 2005 May;235(2):623-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorocholine PET/CT in patients with prostate cancer: initial experience.
  • Patients with newly diagnosed prostate cancer and patients suspected of having recurrent prostate cancer were prospectively evaluated with fluorine 18 fluorocholine (FCH) combined in-line positron emission tomography (PET) and computed tomography (CT).
  • In nine patients evaluated at initial staging, histologic findings of the resected prostate were compared to FCH uptake.
  • Differentiation of benign hyperplasia from cancerous prostate lesions was not possible with FCH PET/CT.
  • However, in patients with recurrent prostate cancer, FCH PET/CT is a promising imaging modality for detecting local recurrence and lymph node metastases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Fluorine Radioisotopes. Image Enhancement. Image Interpretation, Computer-Assisted. Neoplasm Recurrence, Local / diagnosis. Positron-Emission Tomography. Prostatic Neoplasms / diagnosis. Quaternary Ammonium Compounds. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Aged, 80 and over. Bone Neoplasms / diagnosis. Bone Neoplasms / pathology. Bone Neoplasms / secondary. Humans. Male. Middle Aged. Neoplasm Staging. Pelvic Neoplasms / diagnosis. Pelvic Neoplasms / pathology. Pelvic Neoplasms / secondary. Prostate / pathology. Sensitivity and Specificity. Tissue Distribution

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2005.
  • (PMID = 15858102.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Quaternary Ammonium Compounds; 0 / fluoromethyl dimethyl-2-hydroxyethylammonium
  •  go-up   go-down


Advertisement
4. Kirsh VA, Peters U, Mayne ST, Subar AF, Chatterjee N, Johnson CC, Hayes RB, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst; 2007 Aug 1;99(15):1200-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of fruit and vegetable intake and risk of prostate cancer.
  • BACKGROUND: Several epidemiologic studies have reported associations between fruit and vegetable intake and reduced risk of prostate cancer, but the findings are inconsistent and data on clinically relevant advanced prostate cancer are limited.
  • METHODS: We evaluated the association between prostate cancer risk and intake of fruits and vegetables in 1338 patients with prostate cancer among 29,361 men (average follow-up = 4.2 years) in the screening arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
  • RESULTS: Vegetable and fruit consumption was not related to prostate cancer risk overall; however, risk of extraprostatic prostate cancer (stage III or IV tumors) decreased with increasing vegetable intake (RR = 0.41, 95% CI = 0.22 to 0.74, for high versus low intake; P(trend) = .01).
  • We found some evidence that risk of aggressive prostate cancer decreased with increasing spinach consumption, but the findings were not consistently statistically significant when restricted to extraprostatic disease.
  • CONCLUSION: High intake of cruciferous vegetables, including broccoli and cauliflower, may be associated with reduced risk of aggressive prostate cancer, particularly extraprostatic disease.
  • [MeSH-major] Adenocarcinoma / epidemiology. Fruit. Prostatic Neoplasms / epidemiology. Vegetables

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17652276.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


5. Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O'Donoghue J, Larson S, Scher HI: Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol; 2009 May 20;27(15):2436-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
  • PURPOSE: Early studies of patients with castration-resistant metastatic prostate cancer (CRMPC) suggest that chemotherapy administered with a dose of a bone-seeking radiopharmaceutical is superior to chemotherapy alone.
  • Fifteen patients demonstrated a more than 50% decline in prostate-specific antigen.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analgesics, Non-Narcotic / administration & dosage. Analgesics, Non-Narcotic / adverse effects. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Bone and Bones / drug effects. Drug Resistance, Neoplasm. Humans. Male. Maximum Tolerated Dose. Middle Aged. Organometallic Compounds / administration & dosage. Organometallic Compounds / adverse effects. Organophosphorus Compounds / administration & dosage. Organophosphorus Compounds / adverse effects. Prostate-Specific Antigen / blood. Prostate-Specific Antigen / drug effects. Radiopharmaceuticals / administration & dosage. Radiopharmaceuticals / adverse effects. Taxoids / administration & dosage. Taxoids / adverse effects

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Lancet. 2001 Feb 3;357(9253):336-41 [11210994.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):783-91 [15252851.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4925-35 [15983391.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3361-7 [16740758.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):637-43 [17167764.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1148-59 [18309951.001]
  • [Cites] Clin Genitourin Cancer. 2008 Mar;6(1):40-5 [18501082.001]
  • [CommentIn] J Clin Oncol. 2009 May 20;27(15):2417-8 [19364953.001]
  • [ErratumIn] J Clin Oncol. 2011 Oct 10;29(29):3947-8
  • (PMID = 19364960.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA102544; United States / NCI NIH HHS / CA / CA102544
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 0 / Organometallic Compounds; 0 / Organophosphorus Compounds; 0 / Radiopharmaceuticals; 0 / Taxoids; 15H5577CQD / docetaxel; 745X144DZY / samarium Sm-153 lexidronam; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC2684850
  •  go-up   go-down


6. Yin Y, Ni J, Chen M, DiMaggio MA, Guo Y, Yeh S: The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3. Clin Cancer Res; 2007 Apr 1;13(7):2271-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3.
  • PURPOSE: Insulin-like growth factor binding protein-3 (IGFBP-3) is a well-known antiproliferative and proapoptotic molecule in prostate cancer, suggesting that targeting IGFBP-3 might produce clinical benefits.
  • In prostate cancer cells, RRR-alpha-vitamin E succinate (VES) inhibits cell proliferation and induces apoptosis, yet the mechanisms remain to be elucidated.
  • We hypothesize that the protective effects of VES in prostate cancer are mediated by IGFBP-3 up-regulation.
  • Using prostate cancer models, the involvement of IGFBP-3 in the anticancer effect of VES was investigated.
  • EXPERIMENTAL DESIGN: IGFBP-3 mRNA and protein were determined by real-time PCR and Western blotting in prostate cancer cells, xenografted tumors of nude mice, and prostate tumors of transgenic adenocarcinoma mouse prostate (TRAMP) mice.
  • RESULTS: We found that VES induced IGFBP-3 mRNA and protein levels in human prostate cancer cell lines.
  • Notably, the therapeutic and preventive efficacy of VES correlated with increased accumulation of IGFBP-3 in mouse serum as well as in the xenograft tumors and TRAMP prostate samples.
  • CONCLUSIONS: VES mediates its therapeutic and preventive effects against prostate cancer at least partially through up-regulating IGFBP-3, which inhibits cell proliferation and promotes cell apoptosis.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Insulin-Like Growth Factor Binding Protein 3 / drug effects. Prostatic Neoplasms / drug therapy. Vitamin E / analogs & derivatives

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin E.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17404112.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK60912
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 1406-18-4 / Vitamin E; 1406-66-2 / Tocopherols
  •  go-up   go-down


7. Nariculam J, Freeman A, Bott S, Munson P, Cable N, Brookman-Amissah N, Williamson M, Kirby RS, Masters J, Feneley M: Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors. Asian J Androl; 2009 Jan;11(1):109-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
  • A cure cannot be assured for all men with clinically localized prostate cancer undergoing radical treatment.
  • Eighty-two patients comprising 41 case pairs were matched for pathological stage, Gleason grade and preoperative prostate-specific antigen (PSA) concentration.
  • Ki-67, p53 and BCL-2, but not E-cadherin, were significantly upregulated in prostate adenocarcinoma compared with benign prostate tissue (P < 0.01).
  • This study showed that expression of p53, BCL-2 and Ki-67 was upregulated in clinically localized prostate cancer compared with benign prostate tissue, with no alteration in E-cadherin expression.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cadherins / metabolism. Gene Expression Profiling. Ki-67 Antigen / metabolism. Prostatic Neoplasms / diagnosis. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Case-Control Studies. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Prognosis. Prostate / metabolism. Prostate / pathology. Prostate-Specific Antigen / blood. Prostatectomy. Risk Factors


8. Yoon KA, Gil HJ, Han J, Park J, Lee JS: Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer. J Thorac Oncol; 2010 Jan;5(1):10-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer.
  • Increased expression of the transcriptional repressor EZH2 has been reported to be associated with poor prognosis in various malignancies including breast cancer and prostate cancer.
  • Altered expression of EZH2 was also demonstrated in lung cancer, suggesting an involvement in the progression of lung cancer.
  • METHODS: All 41 polymorphisms in EZH2 were genotyped in 335 patients with lung cancer and 335 age- and gender-matched healthy controls.
  • RESULTS: Two polymorphisms of EZH2, rs6950683 and rs3757441, showed a statistically significant association with reduced risk of lung cancer (adjusted OR [aOR] = 0.71, p = 0.007; aOR = 0.73, p = 0.015, respectively).
  • Two copies of a haplotype (Ht2) of EZH2 also showed a significant association with reduced lung cancer risk (aOR = 0.45, 95% confidence interval = 0.23-0.87).
  • CONCLUSION: This is the first study to show a significant association between polymorphisms of the PcG gene EZH2 and lung cancer risk.
  • This study suggests a correlation between the genotype variants in EZH2 and reduced lung cancer risk and hence presents a possible marker for lung cancer susceptibility.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. DNA-Binding Proteins / genetics. Lung Neoplasms / genetics. Polymorphism, Single Nucleotide / genetics. Small Cell Lung Carcinoma / genetics. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19901851.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Transcription Factors; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Polycomb Repressive Complex 2
  •  go-up   go-down


9. Vollmer RT: Predictive probability of serum prostate-specific antigen for prostate cancer: an approach using Bayes rule. Am J Clin Pathol; 2006 Mar;125(3):336-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive probability of serum prostate-specific antigen for prostate cancer: an approach using Bayes rule.
  • This article introduces the use of Bayes probability rule to calculate age and serum prostate-specific antigen (PSA)-specific positive predictive values (PPVs) for prostate cancer.
  • The PPV is the conditional probability of having prostate cancer, given a value of PSA and a particular age group.
  • The formulation uses values of sensitivity obtained from previously reported studies of more than 2,700 men with prostate cancer, and it uses values of specificity obtained from previously reported studies of more than 99,000 men without prostate cancer.
  • The formulation also introduces the use of a population-based and age-specific probability of prostate cancer, and for this it relies on the National Cancer Institute-sponsored Surveillance, Epidemiology and End Results data.
  • [MeSH-major] Adenocarcinoma / diagnosis. Bayes Theorem. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis


10. Stanko C, Grandinetti L, Baldassano M, Mahmoodi M, Kantor GR: Epidermotropic metastatic prostate carcinoma presenting as an umbilical nodule-Sister Mary Joseph nodule. Am J Dermatopathol; 2007 Jun;29(3):290-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermotropic metastatic prostate carcinoma presenting as an umbilical nodule-Sister Mary Joseph nodule.
  • Carcinoma of the prostate accounts for fewer than 1% of all skin metastases.
  • Cutaneous metastases from prostate carcinoma most often involve the penis, the anterior aspect of the thighs, the suprapubic area, and the perineum, but they also have been reported in the scalp, the chest, the back, and even the face.
  • We report an unusual case of metastatic prostate adenocarcinoma that presented as an umbilical nodule (Sister Mary Joseph nodule) and demonstrated significant epidermotropism histologically.
  • A review of the literature has found only one documented case of prostatic carcinoma metastasizing to the umbilicus, and one other documented case of epidermotropic metastatic prostate carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Prostatic Neoplasms / pathology. Skin Neoplasms / secondary. Umbilicus / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519629.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. John AS, Hu X, Rothman VL, Tuszynski GP: Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: exploring the functional significance in tumor cell invasion. Exp Mol Pathol; 2009 Dec;87(3):184-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We now report that TSP-1 up-regulates TIMP-1 expression in both human breast and prostate cancer cell lines.
  • The effect of TSP-1 on TIMP-1 expression was examined in human breast adenocarcinoma cell lines (MDA-MB-231) and human prostate cancer cell lines (PC3-NI and PC3-ML) treated with exogenous TSP-1.
  • TIMP-1 expression was also examined in TSP-1 stably transfected breast cancer cell line (MDA-MB-435).

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Res. 2004 Jul;120(1):21-6 [15172186.001]
  • [Cites] Cancer Res. 2009 Jul 1;69(13):5292-3 [19549886.001]
  • [Cites] J Biol Chem. 1985 Oct 5;260(22):12240-5 [3930491.001]
  • [Cites] Blood. 1986 May;67(5):1197-209 [3516249.001]
  • [Cites] Exp Cell Res. 1986 Dec;167(2):376-90 [3770094.001]
  • [Cites] Cancer Res. 1987 Aug 1;47(15):4130-3 [3607754.001]
  • [Cites] J Cell Biol. 1987 Nov;105(5):2409-15 [3680388.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(17):6624-8 [1697685.001]
  • [Cites] Mol Biol Cell. 1992 Feb;3(2):181-8 [1550960.001]
  • [Cites] J Cell Biol. 1993 Jan;120(2):513-21 [8421063.001]
  • [Cites] Annu Rev Cell Biol. 1993;9:541-73 [8280471.001]
  • [Cites] Int J Cancer. 1994 Oct 15;59(2):191-5 [7927918.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6504-11 [7527299.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6788-92 [7624320.001]
  • [Cites] Proc Soc Exp Biol Med. 1996 Jul;212(3):199-207 [8677265.001]
  • [Cites] Br J Surg. 1997 Feb;84(2):160-6 [9052425.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):436-41 [9139881.001]
  • [Cites] Exp Cell Res. 1997 Sep 15;235(2):403-12 [9299165.001]
  • [Cites] J Biol Chem. 1998 Feb 6;273(6):3604-10 [9452488.001]
  • [Cites] Exp Cell Res. 2006 Aug 1;312(13):2443-53 [16762342.001]
  • [Cites] Cancer Lett. 2007 Jun 18;251(1):28-35 [17188426.001]
  • [Cites] Circ Res. 2007 May 11;100(9):1308-16 [17413041.001]
  • [Cites] J Biol Chem. 1978 Dec 10;253(23):8609-16 [101549.001]
  • (PMID = 19747478.001).
  • [ISSN] 1096-0945
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA088931-01; United States / NCI NIH HHS / CA / R01 CA088931; United States / NCI NIH HHS / CA / R01 CA088931-01; United States / NCI NIH HHS / CA / R01 CA88931
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Thrombospondin 1; 0 / Tissue Inhibitor of Metalloproteinase-1; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ NIHMS150758; NLM/ PMC2783349
  •  go-up   go-down


12. Ramos J, Uchio E, Aslan M, Concato J: Changes in Gleason scores for prostate cancer: what should we expect from a measurement? J Investig Med; 2010 Apr;58(4):625-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in Gleason scores for prostate cancer: what should we expect from a measurement?
  • BACKGROUND: Men diagnosed with prostate cancer receive therapy based on various clinical characteristics, including the Gleason score, a measurement (range, 2-10) describing a tumor's histological appearance.
  • RESULTS: Among men diagnosed with prostate cancer at VA Connecticut, Gleason scores 2 to 4 were reported for 11.4% (19/167) of specimens in 1994-1995 but only 0.4% (1/260) of specimens in 2004-2005; this difference persisted after adjusting for age, clinical stage, and prostate-specific antigen (P < 0.001).
  • CONCLUSIONS: Recent shifts in Gleason scores have led to fewer patients being diagnosed with low-grade prostate cancer; this change can have adverse impacts in clinical care and research.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Humans. Male. Middle Aged. Neoplasm Staging. Observer Variation. Prognosis. Prostate-Specific Antigen / blood. Time Factors

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20224436.001).
  • [ISSN] 1708-8267
  • [Journal-full-title] Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  • [ISO-abbreviation] J. Investig. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


13. Gotto GT, Cronin AM, Laudone VP: Important considerations in the clinical use of preoperative prostate cancer predictive nomograms. Eur Urol; 2010 Oct;58(4):637-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Important considerations in the clinical use of preoperative prostate cancer predictive nomograms.
  • [MeSH-major] Adenocarcinoma / surgery. Nomograms. Preoperative Care. Prostatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20705389.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


14. Dirix P, Haustermans K, Junius S, Withers R, Oyen R, Van Poppel H: The role of whole pelvic radiotherapy in locally advanced prostate cancer. Radiother Oncol; 2006 Apr;79(1):1-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of whole pelvic radiotherapy in locally advanced prostate cancer.
  • Routine PSA testing has led to diagnosis and treatment of prostate cancer at earlier stages than previously.
  • Although, the incidence of nodal metastases is now lower than in pre-PSA days, more extended pelvic lymphadenectomies have shown the actual rate of lymph node involvement to be higher than had been determined from standard radical prostate surgery.
  • This, together with the improved rates of control of the primary prostate tumour, suggests that elective irradiation of early-stage lymph nodes from prostate cancer should enhance survival in a manner analogous to improvements seen with this approach in other cancers.
  • Although, the absolute incidence of positive nodes in locally advanced prostate cancer warrants elective radiotherapy, it is relatively low and the modest improvements to be expected may be undetected in the results of a small trial.
  • [MeSH-major] Pelvis. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Biomarkers, Tumor / analysis. Clinical Trials as Topic. Humans. Male. Neoplasm Staging. Prospective Studies. Prostate-Specific Antigen / blood. Radiotherapy / adverse effects. Radiotherapy / methods. Radiotherapy Planning, Computer-Assisted. Randomized Controlled Trials as Topic. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631267.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 123
  •  go-up   go-down


15. Alberts SR, Novotny PJ, Sloan JA, Danella J, Bostwick DG, Sebo TJ, Blute ML, Fitch TR, Levitt R, Lieberman R, Loprinzi CL: Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial. Am J Ther; 2006 Jul-Aug;13(4):291-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial.
  • High-grade prostatic intraepithelial neoplasia (HGPIN) has been identified as a premalignant change in the prostate that indicates increased risk of the subsequent development of prostate adenocarcinoma.
  • We therefore conducted a chemoprevention trial assessing the efficacy of flutamide in reducing the rate of prostate adenocarcinoma development in men with HGPIN.
  • Men with biopsyproven HGPIN but no evidence of prostate adenocarcinoma were randomized in a double-blind manner to either flutamide 250 mg/d or a placebo.
  • At 1 year, 14% of men receiving flutamide and 10% of men receiving placebo had developed prostate adenocarcinoma.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Flutamide / therapeutic use. Prostatic Intraepithelial Neoplasia / drug therapy. Prostatic Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16858161.001).
  • [ISSN] 1075-2765
  • [Journal-full-title] American journal of therapeutics
  • [ISO-abbreviation] Am J Ther
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-60276
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 76W6J0943E / Flutamide
  •  go-up   go-down


16. Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ: Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer; 2007 Aug 1;110(3):556-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
  • BACKGROUND: This randomized, noncomparative, multicenter, clinical trial evaluated ixabepilone or mitoxantrone/prednisone (MP) as second-line chemotherapy for taxane-refractory, hormone-refractory, prostate cancer (HRPC).
  • Prostate-specific antigen (PSA) declines of >or=50% were observed in 17% of ixabepilone (95% CI, 7-32) and 20% of second-line MP patients (95% CI, 9-35).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Neoplasms, Hormone-Dependent / drug therapy. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Cross-Over Studies. Epothilones / administration & dosage. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisone / administration & dosage. Prostate-Specific Antigen / blood. Salvage Therapy. Survival Rate. Taxoids / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Ixabepilone .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17577218.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epothilones; 0 / Taxoids; 15H5577CQD / docetaxel; BZ114NVM5P / Mitoxantrone; EC 3.4.21.77 / Prostate-Specific Antigen; K27005NP0A / ixabepilone; VB0R961HZT / Prednisone
  •  go-up   go-down


17. El-Zaatari M, Tobias A, Grabowska AM, Kumari R, Scotting PJ, Kaye P, Atherton J, Clarke PA, Powe DG, Watson SA: De-regulation of the sonic hedgehog pathway in the InsGas mouse model of gastric carcinogenesis. Br J Cancer; 2007 Jun 18;96(12):1855-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De-regulation of the sonic hedgehog pathway in the InsGas mouse model of gastric carcinogenesis.
  • Furthermore, Shh overexpression increased the growth rate of the gastric cancer cell line, AGS.
  • The antiapoptotic protein, bcl-2, was expressed in the stroma of infected mice, along with a second Shh target gene, patched-1 (P=0.0001, stroma of metaplastic gland).
  • [MeSH-minor] Adenocarcinoma. Animals. Cell Line, Tumor. Gastric Mucosa / pathology. Gene Expression Regulation, Neoplastic. Humans. Mice. Mice, Inbred Strains. Neoplasms, Experimental / genetics. Neoplasms, Experimental / pathology. Polymerase Chain Reaction. Precancerous Conditions / genetics. Precancerous Conditions / pathology. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2000 Jan;118(1):36-47 [10611152.001]
  • [Cites] J Surg Oncol. 2007 Jan 1;95(1):55-62 [17192867.001]
  • [Cites] Gastroenterology. 2001 Aug;121(2):317-28 [11487541.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5548-55 [11719506.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4773-80 [12183437.001]
  • [Cites] Gut. 2002 Nov;51(5):628-33 [12377798.001]
  • [Cites] J Immunol. 2002 Nov 15;169(10):5451-7 [12421920.001]
  • [Cites] Dig Dis Sci. 2003 Feb;48(2):257-65 [12643600.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Curr Biol. 2004 Jan 20;14(2):R67-9 [14738752.001]
  • [Cites] Helicobacter. 2004 Aug;9(4):313-23 [15270745.001]
  • [Cites] Dev Dyn. 2004 Sep;231(1):148-60 [15305295.001]
  • [Cites] Int J Cancer. 1990 Jan 15;45(1):90-4 [2105279.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1994;61:177-240 [7715070.001]
  • [Cites] Infect Immun. 1997 Aug;65(8):3218-24 [9234778.001]
  • [Cites] Lab Invest. 2004 Dec;84(12):1631-42 [15502857.001]
  • [Cites] Am J Gastroenterol. 2005 Mar;100(3):581-7 [15743355.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Pathol. 2005 Jun;206(2):186-97 [15818572.001]
  • [Cites] Prostate. 2005 Jul 1;64(2):160-7 [15678501.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1698-705 [15905200.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10822-9 [16322228.001]
  • [Cites] Gastroenterology. 2006 Feb;130(2):619 [16472622.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):14-29 [16831586.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7041-9 [16849549.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9255-9 [11481486.001]
  • (PMID = 17505514.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / Shh protein, mouse
  • [Other-IDs] NLM/ PMC2359963
  •  go-up   go-down


18. Comstock CE, Knudsen KE: The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeutics. Cell Cycle; 2007 Jun 1;6(11):1307-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prostatic adenocarcinomas are dependent on androgen receptor (AR) signaling for growth and progression, in part through the ability of AR to induce G1-S phase cell cycle transition.
  • Given the importance of AR in governing the potentiation of this tumor type, there has been a dedicated interest in dissecting the mechanisms by which AR promotes prostate cancer proliferation and survival.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17568191.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA117846; United States / NCI NIH HHS / CA / R01 CA099996
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Androgen Receptor Antagonists; 0 / Androgens; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 0 / Apoptosis Regulatory Proteins; 0 / Cell Cycle Proteins; 0 / Mitosis Modulators; 0 / Neoplasm Proteins; 0 / Receptors, Androgen
  • [Number-of-references] 91
  •  go-up   go-down


19. Weinmann S, Richert-Boe KE, Van Den Eeden SK, Enger SM, Rybicki BA, Shapiro JA, Weiss NS: Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality: a case-control study. Epidemiology; 2005 May;16(3):367-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality: a case-control study.
  • BACKGROUND: The potential role of prostate cancer screening in reducing mortality is uncertain.
  • To examine whether screening with the prostate-specific antigen (PSA) test or digital rectal examination is associated with reduced prostate cancer mortality, we conducted a population-based case-control study in 4 health maintenance organizations.
  • METHODS: Cases were 769 health plan members who died because of prostate adenocarcinoma during the years 1997-2001.
  • Medical records were used to document all screening tests in the 10 years before and including the date on which prostate cancer was first suspected.
  • Most screening tests were digital rectal examinations; therefore, in the subgroup with no history of PSA screening, the association between digital rectal screening and prostate cancer mortality was similar to the overall association (0.65 [0.48-0.88] among whites; 0.86 [0.53-1.4] among blacks).
  • CONCLUSIONS: Digital rectal screening was associated with a reduced risk of death due to prostate cancer in our population.
  • [MeSH-major] Adenocarcinoma / diagnosis. Mass Screening / methods. Palpation / methods. Prostate-Specific Antigen. Prostatic Neoplasms / diagnosis


20. Cai T, Salvadori A, Nesi G, Detti B, Tinacci G, Zini E, Bartoletti R: Penile metastasis from a T1b prostate carcinoma. Onkologie; 2007 May;30(5):249-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Penile metastasis from a T1b prostate carcinoma.
  • BACKGROUND: Penile metastasis from incidental prostate carcinoma has not been described to date.
  • CASE REPORT: The case of a 72-year-old man affected by penile metastasis from incidental prostate carcinoma is described.
  • In March 1998, the patient underwent prostate surgery for lower urinary tract symptoms related to benign prostatic obstruction.
  • Histological examination revealed an incidental adenocarcinoma of the prostate.
  • The pre-operative prostate-specific antigen (PSA) value was 3.6 ng/ml.
  • A prostate biopsy in the peripheral prostate lobes was negative.
  • The prostate biopsy was repeated and was still negative.
  • Surgical biopsy showed a metastasis from prostate adenocarcinoma and he underwent partial penectomy.
  • CONCLUSION: We underline the uncertainty of the biological behaviour and optimal management of incidentally identified prostate carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Penile Neoplasms / secondary. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Biopsy. Disease Progression. Humans. Incidental Findings. Male. Neoplasm Staging. Palliative Care. Penis / pathology. Prostate / pathology. Prostate-Specific Antigen / blood. Prostatectomy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460419.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


21. Tardy I, Pochon S, Theraulaz M, Emmel P, Passantino L, Tranquart F, Schneider M: Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55. Invest Radiol; 2010 Oct;45(10):573-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55.
  • OBJECTIVES: To evaluate BR55, a new VEGFR2-specific ultrasound contrast agent, for imaging prostate tumors in an orthotopic model in the rat.
  • MATERIALS AND METHODS: Rat prostate adenocarcinoma were established by injection of G Dunning R-3327 tumor cells in one lobe of the prostate of Copenhagen rats.
  • Contrast enhancement in the tumor and healthy prostate was followed over time by intermittent imaging at low acoustic power.
  • Immunohistochemistry was performed on the prostate and tumor specimen to determine the expression of VEGFR2.
  • Then, once unbound microbubbles had cleared from the circulation, a strong enhancement of the tumor was obtained with BR55, whereas no significant microbubble accumulation was detected in the healthy prostate tissue.
  • The tumor to prostate ratio calculated after signal quantification was about 20 for the 3 doses of BR55 tested.
  • CONCLUSIONS: This study showed that BR55 binding to prostate tumors resulted in a strong enhancement of the lesions as early as a few minutes after contrast injection, whereas minimal nonspecific accumulation occurred in the healthy part of the gland.
  • The late phase enhancement of the tumor should be particularly valuable for prostate cancer detection and for biopsy guidance.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Molecular Imaging / methods. Prostate / radionuclide imaging. Prostatic Neoplasms / radionuclide imaging. Vascular Endothelial Growth Factor Receptor-2 / drug effects

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20808233.001).
  • [ISSN] 1536-0210
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


22. Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T, Karamanolakis D, Halapas A, Tenta R, Katopodis H, Papageorgiou E, Pitulis N, Pissimissis N, Lembessis P, Sourla A: Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach. Expert Opin Investig Drugs; 2006 Jul;15(7):795-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
  • The development of resistance to anticancer therapies is a major hurdle in preventing long-lasting clinical responses to conventional therapies in hormone-refractory prostate cancer.
  • Herein, the molecular evidence documenting that bone metastasis microenvironment survival factors (mainly the paracrine growth hormone-independent, urokinase-type plasminogen activator-mediated increase of IGF-1 and the endocrine production of growth hormone-dependent IGF-1, mainly liver-derived IGF-1 production) produce an epigenetic form of prostate cancer cells that are resistant to proapoptotic therapies is reviewed.
  • Consequently, the authors present the conceptual framework of a novel antibone microenvironment survival factor, mainly an anti-IGF-1 hormonal manipulation for androgen ablation refractory prostate cancer (a combination of conventional androgen ablation therapy [luteinising hormone-releasing hormone agonist-A or orchiectomy]) with dexamethasone plus somatostatin analogue, which yielded durable objective responses and major improvement of bone pain and performance status in stage D3 prostate cancer patients.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Prostatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16787142.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Androgens; 0 / Antineoplastic Agents, Hormonal; 0 / Growth Substances; 0 / Neoplasm Proteins; 0 / Peptides, Cyclic; 0 / Receptors, Androgen; 118992-92-0 / lanreotide; 33515-09-2 / Gonadotropin-Releasing Hormone; 35LT29625A / Estramustine; 51110-01-1 / Somatostatin; 57773-63-4 / Triptorelin Pamoate; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; EFY6W0M8TG / Leuprolide
  • [Number-of-references] 79
  •  go-up   go-down


23. Biade S, Marinucci M, Schick J, Roberts D, Workman G, Sage EH, O'Dwyer PJ, Livolsi VA, Johnson SW: Gene expression profiling of human ovarian tumours. Br J Cancer; 2006 Oct 23;95(8):1092-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is currently a lack of reliable diagnostic and prognostic markers for ovarian cancer.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biotechniques. 2000 Sep;29(3):548-50, 552-4, 556 passim [10997270.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):626-9 [9485012.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):521-6 [11179481.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1A):65-70 [11299791.001]
  • [Cites] Eur J Cancer. 2001 Jun;37(9):1158-65 [11378347.001]
  • [Cites] Int J Gynecol Cancer. 2001 Nov-Dec;11(6):454-61 [11906548.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):34-7 [12079297.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4722-9 [12183431.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1215-21 [12368195.001]
  • [Cites] Int J Cancer. 2003 Apr 10;104(3):289-302 [12569552.001]
  • [Cites] Leuk Lymphoma. 2003 Mar;44(3):439-44 [12688312.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5778-82 [12732717.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jul;22(3):240-7 [12819390.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Aug;17(4):909-25, vii [12959182.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4906-13 [14581365.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1599-604 [14583755.001]
  • [Cites] Mol Biol Cell. 2003 Nov;14(11):4376-86 [12960427.001]
  • [Cites] J Exp Ther Oncol. 2003 Nov-Dec;3(6):297-304 [14678518.001]
  • [Cites] Prostate. 2004 Feb 1;58(2):183-92 [14716744.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):305-14 [9633842.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):372-80 [9633850.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):686-92 [14760385.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):1045-52 [14983501.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):364-75 [14996858.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1620-6 [15083195.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] J Histochem Cytochem. 2004 Jun;52(6):735-48 [15150282.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Mar;87(5):1663-7 [1689846.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1810-20 [8383580.001]
  • [Cites] Gynecol Oncol. 1994 Feb;52(2):247-52 [8314147.001]
  • [Cites] Science. 1995 Oct 20;270(5235):467-70 [7569999.001]
  • [Cites] J Cell Biol. 1997 May 19;137(4):899-908 [9151692.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Br J Cancer. 2000 Mar;82(6):1123-30 [10735494.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1535-8 [10789720.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1176-81 [11158614.001]
  • (PMID = 16969345.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM040711; United States / NIGMS NIH HHS / GM / GM40711; United States / NCI NIH HHS / CA / U01-CA85059
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Calcium-Binding Proteins; 0 / Extracellular Matrix Proteins; 0 / SPARCL1 protein, human
  • [Other-IDs] NLM/ PMC2360705
  •  go-up   go-down


24. Park EA, Lee HJ, Kim KG, Kim SH, Lee SE, Choe GY: Prediction of pathological stages before prostatectomy in prostate cancer patients: analysis of 12 systematic prostate needle biopsy specimens. Int J Urol; 2007 Aug;14(8):704-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of pathological stages before prostatectomy in prostate cancer patients: analysis of 12 systematic prostate needle biopsy specimens.
  • OBJECTIVE: To identify the most reliable predictor of the pathological stage among multiple parameters obtained by performing systematic biopsies and to assess the predictive value of any identified parameters in combination with the prostate specific antigen and the Gleason scores.
  • METHODS: We examined 5 biopsy parameters from 12 systematic needle biopsy results in 104 consecutive prostate cancer patients who underwent prostatectomy: the number of cores positive for cancer, percentage of positive biopsy cores, total linear cancer length (absolute sum of tumor length at each core), percentage cancer length (total cancer length divided by total length of cores obtained x100), and maximum cancer core length.
  • RESULTS: Of 104 patients, 85 (82.9%) had organ confined cancer and 19 (17.1%) showed extraprostatic extension.
  • Of the five parameters examined, maximum cancer length was found to best predict pathological staging.
  • Although insignificant, adding results of maximum cancer length to prostate specific antigen and Gleason scores improved predictability.
  • Of 41 patients with a maximum cancer length of <0.9 cm, PSA of <16 ng/mL, and Gleason score of <7, none showed extraprostatic extension.
  • CONCLUSIONS: The maximum cancer length was found to be the most reliable predictor of disease staging.
  • The findings of a maximum cancer length of <0.9 cm, PSA of <16 ng/mL, and a Gleason score of <7 can suggest an organ-confined disease.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Neoplasm Staging. Prostatectomy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery


25. Hekal IA: The patients less than 50 years: is there a need to lower the PSA cutoff point? Prostate Cancer Prostatic Dis; 2009;12(2):148-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to study the incidence and possibility of prostate cancer detection in patients <50 years with prostate-specific antigen (PSA) <4 ng ml(-1).
  • Between January 2006 and January 2008, 355 men were subjected to radical cystoprostatectomy for bladder cancer.
  • Among 162 cases without pathological prostatic invasion, random selection of two groups with serum PSA <4 ng ml(-1) was carried out.
  • The resected prostate glands of each group were examined pathologically for evidence of prostatic adenocarcinoma.
  • Prostatic adenocarcinoma was detected in 1.8 and 10.7% in groups A and B, respectively (P=0.051).
  • High-grade prostatic intraepithelial neoplasia (PIN) was higher in group A than in group B, 11 cases versus 4 (P=0.079).
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / diagnosis. Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Age Factors. Body Mass Index. Humans. Incidence. Male. Middle Aged. Prostatic Intraepithelial Neoplasia / blood. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Intraepithelial Neoplasia / epidemiology


26. Manikandan R, Nathaniel C, Reeve N, Brough RJ: Bilateral testicular metastases from prostatic carcinoma. Int J Urol; 2006 Apr;13(4):476-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral testicular metastases from prostatic carcinoma.
  • Testicular metastasis from carcinoma of the prostate is rare.
  • We report a case of carcinoma of the prostate with bilateral testicular metastases 7 years after the initial diagnosis.
  • [MeSH-major] Adenocarcinoma / secondary. Prostatic Neoplasms / pathology. Testicular Neoplasms / secondary
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Male. Middle Aged. Orchiectomy. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734881.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


27. Zhang GY, Ahmed N, Riley C, Oliva K, Barker G, Quinn MA, Rice GE: Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer; 2005 Jan 17;92(1):113-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies have demonstrated the expression of PPARgamma in several tumours including colon, breast, bladder, prostate, lung and stomach.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Blotting, Western. Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Female. Humans. Immunohistochemistry. Ovary / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):752-7 [12866036.001]
  • [Cites] Oncogene. 2003 Jun 19;22(25):3888-900 [12813462.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(17):6159-73 [12917338.001]
  • [Cites] Oncogene. 2003 Aug 21;22(35):5446-50 [12934104.001]
  • [Cites] Arch Pathol Lab Med. 2003 Sep;127(9):1121-3 [12946234.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4440-5 [12970322.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4627-35 [14555539.001]
  • [Cites] Minerva Ginecol. 2003 Aug;55(4):297-314 [14581855.001]
  • [Cites] Nat Immunol. 2004 Jan;5(1):104-12 [14691478.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2004 Feb;286(2):E201-7 [14701665.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Mar 5;315(2):497-501 [14766236.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1181-9 [14871855.001]
  • [Cites] Gut. 2004 Mar;53(3):331-8 [14960510.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):355-66 [14764655.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(8):3430-44 [15060163.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2415-20 [15073119.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7355-9 [8041794.001]
  • [Cites] Eur J Biochem. 1996 Jul 1;239(1):1-7 [8706692.001]
  • [Cites] Curr Opin Cell Biol. 1998 Jun;10(3):384-91 [9640540.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1053-7 [9734399.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6 [10097144.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):2011-7 [10213514.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Mutat Res. 2000 Mar 17;448(2):139-51 [10725468.001]
  • [Cites] Nature. 2000 May 25;405(6785):421-4 [10839530.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3241-8 [10955810.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5 [10984506.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5494-8 [11034093.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1394-400 [11044367.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13275-80 [11087869.001]
  • [Cites] Toxicol Lett. 2000 Dec 20;118(1-2):79-86 [11137312.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2598-603 [11226285.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):483-90 [11228540.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5307-10 [11431375.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Oct;127(10):1253-9 [11587608.001]
  • [Cites] Annu Rev Med. 2002;53:409-35 [11818483.001]
  • [Cites] J Biol Chem. 2002 May 17;277(20):17830-5 [11884400.001]
  • [Cites] Lung Cancer. 2002 Jun;36(3):249-55 [12009233.001]
  • [Cites] Mol Hum Reprod. 2002 Jun;8(6):574-9 [12029076.001]
  • [Cites] Invest New Drugs. 2002 May;20(2):195-200 [12099579.001]
  • [Cites] Jpn J Clin Oncol. 2002 Jul;32(7):238-43 [12324573.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):597-602 [12594814.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):11945-53 [12551936.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3198-203 [12912973.001]
  • (PMID = 15583697.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / PPAR gamma
  • [Other-IDs] NLM/ PMC2361744
  •  go-up   go-down


28. Braun KP, Brookman-Amissah S, May M, Grassmel Y, Hoschke B, Braun V: [The assessment of pathological PSA values by the general practitioner--observation or intervention?]. Aktuelle Urol; 2009 May;40(3):171-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: 406 patients who underwent ultrasound-guided transrectal biopsy of the prostate were assessed retrospectively.
  • The median time interval between assessment of the pathological PSA value and prostate biopsy amounted to at least 20 weeks in the case of a pathological PSA value in the first measurement and up to a maximum of 43 weeks in the case of a further control of an already increased PSA value.
  • Altogether 47 cases of prostate cancer were detected.
  • In 40 of these patients with histologically proven prostate cancer, the pathological PSA value had previously been assessed by the general practitioner.
  • CONCLUSION: In the majority of cases, an elevated PSA value resulted in a contemporary diagnostic course using transrectal biopsy of the prostate.
  • In particular cases a further control measurement of PSA was accomplished, which resulted in an unacceptable delay regarding the histological confirmation of the diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / blood. Patient Care Team. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy. Endosonography. Family Practice. Humans. Male. Middle Aged. Neoplasm Staging. Prostate / pathology. Referral and Consultation. Retrospective Studies. Time and Motion Studies


29. Henderson A, Andreyev HJ, Stephens R, Dearnaley D: Patient and physician reporting of symptoms and health-related quality of life in trials of treatment for early prostate cancer: considerations for future studies. Clin Oncol (R Coll Radiol); 2006 Dec;18(10):735-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient and physician reporting of symptoms and health-related quality of life in trials of treatment for early prostate cancer: considerations for future studies.
  • AIMS: Clinical trials in early prostate cancer (EPC) have used a variety of outcome measures, including patient-reported outcomes (PROs) and physician-reported data.
  • MATERIALS AND METHODS: A literature search combining the terms 'quality of life' or 'symptoms' and 'prostate cancer' or 'prostate adenocarcinoma' was carried out.
  • [MeSH-major] Clinical Trials as Topic / methods. Prostatic Neoplasms / psychology. Prostatic Neoplasms / therapy. Quality of Life. Research Design. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168208.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501019
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Culhaci N, Sagol O, Karademir S, Astarcioglu H, Astarcioglu I, Soyturk M, Oztop I, Obuz F: Expression of transforming growth factor-beta-1 and p27Kip1 in pancreatic adenocarcinomas: relation with cell-cycle-associated proteins and clinicopathologic characteristics. BMC Cancer; 2005;5:98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We examined TGF-beta1 and p27 expression immunohistochemically in 63 cases of invasive ductal adenocarcinoma of the pancreas.
  • But it is not associated with cell cycle proteins. p27 expression is reduced in pancreatic adenocarcinomas and decreased protein levels of p27 may play a role in the differentiation of pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / biosynthesis. Immunohistochemistry / methods. Pancreatic Neoplasms / metabolism. Transforming Growth Factor beta / biosynthesis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. BIOTIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Ther. 2003 May;98(2):257-65 [12725873.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1129-36 [10514396.001]
  • [Cites] J Clin Gastroenterol. 2003 Jul;37(1):23-7 [12811204.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jul;33(7):346-52 [12949061.001]
  • [Cites] Dig Dis Sci. 2004 May;49(5):828-32 [15259505.001]
  • [Cites] Surgery. 2004 Aug;136(2):364-74 [15300203.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1846-56 [8253361.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3929-34 [9307274.001]
  • [Cites] Dig Dis Sci. 1997 Oct;42(10):2054-63 [9365135.001]
  • [Cites] J Urol. 1998 Mar;159(3):941-5 [9474188.001]
  • [Cites] Am J Clin Pathol. 1998 Jul;110(1):16-23 [9661918.001]
  • [Cites] Prostate. 1998 Sep 15;37(1):19-29 [9721065.001]
  • [Cites] Jpn J Clin Oncol. 1998 Sep;28(9):534-7 [9793024.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(4):383-91 [9931387.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):123-9 [10029438.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1011-7 [10091782.001]
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):27-34 [10585578.001]
  • [Cites] J Clin Pathol. 1999 Aug;52(8):555-68 [10645224.001]
  • [Cites] J Urol. 2000 Dec;164(6):1987-91 [11061897.001]
  • [Cites] J Urol. 2000 Dec;164(6):2156-61 [11061947.001]
  • [Cites] Teratog Carcinog Mutagen. 2001;21(1):27-44 [11135319.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(2):224-33 [11166150.001]
  • [Cites] Pathol Int. 2001 Feb;51(2):94-9 [11169147.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):4-9 [11172288.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(5):489-95 [11180876.001]
  • [Cites] J Surg Res. 2001 Apr;96(2):284-8 [11266285.001]
  • [Cites] Pancreas. 2001 May;22(4):341-7 [11345133.001]
  • [Cites] Int J Cancer. 2001 Sep 20;95(5):302-6 [11494229.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S44-51 [11684442.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1808-15 [12060621.001]
  • [Cites] Oncogene. 2003 Jan 23;22(3):319-29 [12545153.001]
  • [Cites] J Oral Pathol Med. 2003 Mar;32(3):139-45 [12581383.001]
  • [Cites] J Hepatol. 2003 May;38(5):591-7 [12713869.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1250-60 [10189129.001]
  • [Cites] Am J Surg. 1999 Mar;177(3):209-15 [10219856.001]
  • [Cites] Eur J Surg. 1999 Apr;165(4):292-306 [10365829.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):678-85 [10366150.001]
  • [Cites] Auris Nasus Larynx. 2003 May;30(2):163-8 [12753988.001]
  • (PMID = 16086840.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 6SO6U10H04 / Biotin; 9013-20-1 / Streptavidin
  • [Other-IDs] NLM/ PMC1208869
  •  go-up   go-down


31. Martín-Orozco RM, Almaraz-Pro C, Rodríguez-Ubreva FJ, Cortés MA, Ropero S, Colomer R, López-Ruiz P, Colás B: EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt. Neoplasia; 2007 Aug;9(8):614-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary focus of this investigation was to study the relationship between neuroendocrine (NE) differentiation and epidermal growth factor (EGF) because both have been implicated in the progression of prostate cancer.
  • Altogether, the present data should be borne in mind when designing new clinical schedules for the treatment of prostate cancer, including the use of ErbB receptors and associated signaling pathway inhibitors.
  • [MeSH-major] Adenocarcinoma / pathology. Androgens. Epidermal Growth Factor / pharmacology. MAP Kinase Signaling System / drug effects. Neoplasm Proteins / physiology. Neoplasms, Hormone-Dependent / pathology. Phosphatidylinositol 3-Kinases / physiology. Prostatic Neoplasms / pathology. Proto-Oncogene Proteins c-akt / physiology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1994 Oct 15;54(20):5474-8 [7522959.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5330-4 [8202489.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):12052-6 [9115272.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):4997-5000 [9371490.001]
  • [Cites] Urol Int. 1997;59(3):149-53 [9428430.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2720-3 [9661880.001]
  • [Cites] Prostate Suppl. 1998;8:43-51 [9690663.001]
  • [Cites] Clin Cancer Res. 1995 May;1(5):545-50 [9816014.001]
  • [Cites] Nat Med. 1999 Mar;5(3):280-5 [10086382.001]
  • [Cites] Prostate. 1999 May;39(2):135-48 [10221570.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5458-63 [10318905.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2891-7 [10383151.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3821-30 [10447001.001]
  • [Cites] Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70 [10482195.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5030-6 [10519419.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):517-27 [15542435.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):455-60 [15659491.001]
  • [Cites] Eur Urol. 2005 Feb;47(2):147-55 [15661408.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):846-53 [15720812.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] Hum Pathol. 2005 May;36(5):562-70 [15948124.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3159-67 [10880430.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Biochem J. 2001 May 15;356(Pt 1):87-96 [11336639.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 15):71-6 [11685733.001]
  • [Cites] Mol Cell Biol. 2001 Dec;21(24):8471-82 [11713282.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S141-4 [11762342.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8887-95 [11751413.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1549-54 [11888934.001]
  • [Cites] Mol Biol Cell. 2002 Jul;13(7):2547-57 [12134089.001]
  • [Cites] J Urol. 2002 Sep;168(3):1204-11 [12187268.001]
  • [Cites] Prostate. 2002 Oct 1;53(2):118-23 [12242726.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4292-302 [12409327.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1274-83 [12684395.001]
  • [Cites] BJU Int. 2003 Dec;92(9):890-5 [14632841.001]
  • [Cites] J Cell Biochem. 2004 Mar 1;91(4):671-83 [14991759.001]
  • [Cites] Eur Urol. 2004 May;45(5):586-92; discussion 592 [15082200.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5232-6 [15289328.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):117-27 [15324695.001]
  • [Cites] Cancer Res. 1967 Nov;27(11):1925-30 [5624120.001]
  • [Cites] Prostate. 1991;19(2):91-8 [1717965.001]
  • [Cites] Urology. 1993 Nov;42(5):512-9 [7694415.001]
  • [Cites] J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):401-5 [7626487.001]
  • (PMID = 17898861.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Androgens; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Culture Media, Serum-Free; 0 / Neoplasm Proteins; 0 / Quinazolines; 62229-50-9 / Epidermal Growth Factor; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; P188ANX8CK / Trastuzumab; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ PMC1950431
  • [Keywords] NOTNLM ; EGF / gefinitib / neuroendocrine differentiation / prostate cancer / trastuzumab
  •  go-up   go-down


32. Berger JR, Bensalem M, Dalmau J: A brainstem paraneoplastic syndrome associated with prostate cancer. J Neurol Neurosurg Psychiatry; 2009 Aug;80(8):934-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A brainstem paraneoplastic syndrome associated with prostate cancer.
  • BACKGROUND: Paraneoplastic syndromes are seldom observed with prostate cancer.
  • A rare paraneoplastic brainstem syndrome associated with prostate cancer is described, and the presence of antineuronal antibodies with this syndrome is demonstrated for the first time.
  • PATIENT: This 59-year-old man developed ophthalmoplegia, dysarthria, dysphagia, pruritus, ataxia, corticobulbar and corticospinal signs in association with prostate cancer.
  • The disorder was unaffected by treatment of the underlying malignancy, but responded initially to high-dose corticosteroid administration and intravenous immunoglobulins.
  • CONCLUSIONS: This unique paraneoplastic syndrome chiefly affecting the brainstem may be a diagnostic clue to the presence of unsuspected prostate adenocarcinoma.
  • [MeSH-major] Brain Stem Neoplasms / complications. Paraneoplastic Syndromes, Nervous System / complications. Prostatic Neoplasms / complications

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19608787.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Immunoglobulins, Intravenous
  •  go-up   go-down


33. Young JG, Green NK, Mautner V, Searle PF, Young LS, James ND: Combining gene and immunotherapy for prostate cancer. Prostate Cancer Prostatic Dis; 2008;11(2):187-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combining gene and immunotherapy for prostate cancer.
  • The nitroreductase (NR)/CB1954 enzyme prodrug system has given promising results in pre-clinical studies and is currently being assessed in phase I and II clinical trials in prostate cancer.
  • Enhanced cell killing by apparent immune-mediated mechanisms has been shown in pancreatic and colorectal cancer models, by co-expressing murine granulocyte macrophage colony-stimulating factor (GM-CSF) with NR in a single replication deficient adenoviral vector.
  • To examine if similar enhancement of tumour cell killing could be produced in prostate cancer, the TRAMP model was chosen.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / therapeutic use. Aziridines / therapeutic use. Escherichia coli Proteins / metabolism. Genes, Transgenic, Suicide. Genetic Therapy. Genetic Vectors / therapeutic use. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Immunotherapy. Nitroreductases / metabolism. Prodrugs / therapeutic use. Prostatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17726452.001).
  • [ISSN] 1476-5608
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / /
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Aziridines; 0 / Escherichia coli Proteins; 0 / Prodrugs; 0 / Recombinant Proteins; 7865D5D01M / tretazicar; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; EC 1.7.- / NfsA protein, E coli; EC 1.7.- / Nitroreductases
  •  go-up   go-down


34. Adley BP, Yang XJ: Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review. Anal Quant Cytol Histol; 2006 Feb;28(1):1-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review.
  • Alpha-methylacyl coenzyme A racemase (AMACR) is a recently discovered enzyme protein that has been shown to be increased at both the mRNA and protein levels in prostatic adenocarcinoma as compared with normal prostatic tissues.
  • Since its discovery, AMACR has gained wide acceptance for use in the diagnosis of prostatic adenocarcinoma in conjunction with morphology and immunohistochemical staining for basal cell markers.
  • Numerous studies have consistently shown high sensitivity and specificity of AMACR for prostate cancer.
  • This review focuses on AMACR expression in prostate cancer and its morphologic variants, high grade prostatic intraepithelial neoplasia, adenosis and benign conditions of the prostate.
  • Finally, we emphasize diagnostic pitfalls in the application of AMACR to small, atypical foci of glands seen on prostate needle core biopsy and project future diagnostic as well as clinical applications for the protein.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566275.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Number-of-references] 63
  •  go-up   go-down


35. Reymann S, Borlak J: Transcription profiling of lung adenocarcinomas of c-myc-transgenic mice: identification of the c-myc regulatory gene network. BMC Syst Biol; 2008;2:46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By using microarray technology, alterations in the expression of genes were captured based on a female transgenic mouse model in which, indeed, c-Myc overexpression in alveolar epithelium results in the development of bronchiolo-alveolar carcinoma (BAC) and papillary adenocarcinoma (PLAC).
  • [MeSH-major] Adenocarcinoma / metabolism. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic / genetics. Lung Neoplasms / metabolism. Models, Biological. Proto-Oncogene Proteins c-myc / genetics. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5313-8 [12702757.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3576-9 [12824369.001]
  • [Cites] Science. 1991 Mar 8;251(4998):1211-7 [2006410.001]
  • [Cites] Oncogene. 1991 Nov;6(11):1941-8 [1658705.001]
  • [Cites] Cell Growth Differ. 1992 Mar;3(3):183-90 [1633109.001]
  • [Cites] EMBO J. 1993 Aug;12(8):3237-47 [8344261.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7804-8 [8356088.001]
  • [Cites] Nucleic Acids Res. 1993 Aug 11;21(16):3767-75 [8367294.001]
  • [Cites] EMBO J. 1993 Dec 15;12(13):5083-7 [8262051.001]
  • [Cites] Genes Dev. 1994 Jul 1;8(13):1526-37 [7958837.001]
  • [Cites] Science. 1995 Jan 20;267(5196):389-93 [7824938.001]
  • [Cites] Mol Cell Biol. 1995 Mar;15(3):1536-44 [7862146.001]
  • [Cites] EMBO J. 1995 Apr 3;14(7):1508-19 [7729426.001]
  • [Cites] Biochemistry. 1995 Dec 19;34(50):16503-8 [8845379.001]
  • [Cites] Cell. 1995 Dec 29;83(7):1101-11 [8548798.001]
  • [Cites] Nucleic Acids Res. 1995 Dec 11;23(23):4878-84 [8532532.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10750-8 [16322220.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17834-9 [17093053.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18580-5 [17132729.001]
  • [Cites] Nucleic Acids Res. 2007;35(4):1098-107 [17264126.001]
  • [Cites] PLoS Comput Biol. 2007 Apr 6;3(4):e63 [17411336.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8164-9 [12808131.001]
  • [Cites] Genome Biol. 2003;4(10):R69 [14519204.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9375-88 [14645547.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(6):2546-59 [14993291.001]
  • [Cites] J Cell Biochem. 2004 Apr 1;91(5):896-903 [15034925.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3459-71 [15213251.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6740-9 [15374992.001]
  • [Cites] Nucleic Acids Res. 2004;32(17):4955-61 [15388797.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 May;86(10):3594-8 [2524830.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):142-6 [10702024.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3260-5 [10737792.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Prostate. 2000 Jun 1;43(4):278-85 [10861747.001]
  • [Cites] Adv Cancer Res. 1996;68:109-82 [8712067.001]
  • [Cites] Br J Cancer. 1996 Aug;74(4):573-8 [8761372.001]
  • [Cites] Nucleic Acids Res. 1997 Mar 15;25(6):1108-16 [9092617.001]
  • [Cites] Diabetes. 1998 Jan;47(1):98-103 [9421381.001]
  • [Cites] Biochem Biophys Res Commun. 1998 May 29;246(3):668-74 [9618270.001]
  • [Cites] Dev Biol. 1998 Oct 15;202(2):183-95 [9769171.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1999;39:103-25 [10331078.001]
  • [Cites] Oncogene. 1999 May 13;18(19):2916-24 [10378688.001]
  • [Cites] Oncogene. 1999 May 13;18(19):2925-33 [10378689.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jun 24;260(1):216-21 [10381369.001]
  • [Cites] Mol Cell. 2004 Nov 19;16(4):521-35 [15546613.001]
  • [Cites] EMBO J. 2005 Jan 26;24(2):336-46 [15616584.001]
  • [Cites] Nat Genet. 2005 Apr;37(4):382-90 [15778709.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 10;102(19):6902-6 [15867157.001]
  • [Cites] EMBO J. 2005 Jul 20;24(14):2590-601 [15990869.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(15):5490-502 [10891489.001]
  • [Cites] Oncogene. 2000 Jun 29;19(28):3200-12 [10918575.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1394-400 [11044367.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5922-8 [11085504.001]
  • [Cites] Nucleic Acids Res. 2001 Jan 1;29(1):281-3 [11125113.001]
  • [Cites] J Biol Chem. 2001 Jan 5;276(1):28-34 [11018030.001]
  • [Cites] Nucleic Acids Res. 2001 Jan 15;29(2):397-406 [11139609.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Apr;280(4):L695-704 [11238010.001]
  • [Cites] EMBO J. 2001 Mar 15;20(6):1383-93 [11250904.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2334-5 [11402330.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):4984-94 [11526483.001]
  • [Cites] Oncogene. 2001 Dec 6;20(56):8116-24 [11781825.001]
  • [Cites] Nucleic Acids Res. 2001 Dec 15;29(24):4994-5000 [11812829.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):11617-20 [11805123.001]
  • [Cites] Cell Death Differ. 2002 May;9(5):513-26 [11973610.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5757-9 [11983876.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6274-9 [11983916.001]
  • [Cites] Development. 2002 Jun;129(11):2723-32 [12015299.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Aug;283(2):G266-9 [12121872.001]
  • [Cites] J Neurooncol. 2002 May;57(3):201-14 [12125983.001]
  • [Cites] Hum Mol Genet. 2002 Aug 1;11(16):1817-21 [12140184.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):166-74 [12185365.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):160-5 [12185367.001]
  • [Cites] J Biol Chem. 2002 Oct 4;277(40):36921-30 [12145275.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1315-23 [12368205.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(22):7877-88 [12391156.001]
  • [Cites] Gene. 2003 Jan 16;303:11-34 [12559563.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8300-8 [12501251.001]
  • (PMID = 18498649.001).
  • [ISSN] 1752-0509
  • [Journal-full-title] BMC systems biology
  • [ISO-abbreviation] BMC Syst Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2430022
  •  go-up   go-down


36. Zhong S, Xu Y, Zhang Z: Construction of eukaryotic expression vector of human CC10 gene and expression of CC10 protein in lung adenocarcinoma A549 cell line. J Huazhong Univ Sci Technolog Med Sci; 2005;25(5):505-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Construction of eukaryotic expression vector of human CC10 gene and expression of CC10 protein in lung adenocarcinoma A549 cell line.
  • 1-hCC10 was constructed and identified, then CC10 protein expression in A549 lung cancer cell line was detected.
  • The segment was then transfected into the A549 lung cancer cell line.
  • [MeSH-major] Adenocarcinoma / metabolism. Genetic Vectors. Lung Neoplasms / metabolism. Uteroglobin / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 1995 Mar;56(3):705-15 [7887426.001]
  • [Cites] Clin Chim Acta. 1992 May 15;207(3):239-49 [1395029.001]
  • [Cites] J Biol Chem. 2004 Jul 9;279(28):29336-40 [15148323.001]
  • [Cites] Ann N Y Acad Sci. 2000;923:78-89 [11193781.001]
  • [Cites] Cell Growth Differ. 1998 Jun;9(6):475-85 [9663466.001]
  • [Cites] Curr Pharm Des. 2003;9(14):1139-49 [12769755.001]
  • [Cites] Eur Respir J. 1997 May;10(5):1108-14 [9163654.001]
  • [Cites] Ann N Y Acad Sci. 2000;923:249-67 [11193761.001]
  • [Cites] Clin Prostate Cancer. 2002 Sep;1(2):118-24 [15046703.001]
  • (PMID = 16463657.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / SCGB1A1 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


37. Xie BX, Zhang H, Yu L, Wang J, Pang B, Wu RQ, Qian XL, Li SH, Shi QG, Wang LL, Zhou JG: The radiation response of androgen-refractory prostate cancer cell line C4-2 derived from androgen-sensitive cell line LNCaP. Asian J Androl; 2010 May;12(3):405-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The radiation response of androgen-refractory prostate cancer cell line C4-2 derived from androgen-sensitive cell line LNCaP.
  • Radiation therapy is a relatively effective therapeutic method for localized prostate cancer (PCa) patients.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Androgens / physiology. Drug Resistance, Neoplasm / radiation effects. Neoplasms, Hormone-Dependent / radiotherapy. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1584-8 [10887152.001]
  • [Cites] Urol Oncol. 2008 Sep-Oct;26(5):522-9 [18774467.001]
  • [Cites] Genes Dev. 2001 Sep 1;15(17):2177-96 [11544175.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1713-6 [11721054.001]
  • [Cites] Cell. 2001 Nov 30;107(5):563-5 [11733056.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105 [12128107.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2003 Jan;3(1):35-46 [12678913.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7190-6 [14612513.001]
  • [Cites] J Urol. 2004 Apr;171(4):1393-401 [15017184.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):241-9 [15380515.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1809-18 [6831420.001]
  • [Cites] NCI Monogr. 1988;(7):95-103 [3050543.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2577-81 [8168083.001]
  • [Cites] Int J Cancer. 1994 May 1;57(3):406-12 [8169003.001]
  • [Cites] Urology. 1995 Apr;45(4):624-31; discussion 631-2 [7716843.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):491-500 [9635694.001]
  • [Cites] Science. 1998 Nov 20;282(5393):1497-501 [9822382.001]
  • [Cites] Genes Dev. 1999 May 15;13(10):1276-88 [10346816.001]
  • [Cites] Urol Clin North Am. 1999 May;26(2):263-73 [10361549.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4375-82 [10485486.001]
  • [Cites] Semin Radiat Oncol. 2006 Jan;16(1):20-8 [16378903.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):382-8 [16965990.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Oncogene. 2007 Feb 26;26(9):1324-37 [17322918.001]
  • [Cites] Endocr Relat Cancer. 2007 Sep;14(3):633-43 [17914094.001]
  • [Cites] Rev Assoc Med Bras. 2008 Mar-Apr;54(2):178-82 [18506331.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Aug;9(8):616-27 [18594563.001]
  • [Cites] Cancer Invest. 1999;17(1):56-72 [10999050.001]
  • (PMID = 20118949.001).
  • [ISSN] 1745-7262
  • [Journal-full-title] Asian journal of andrology
  • [ISO-abbreviation] Asian J. Androl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Androgens; 0 / DNA, Neoplasm; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue
  • [Other-IDs] NLM/ PMC3739257
  •  go-up   go-down


38. Spinola M, Leoni VP, Galvan A, Korsching E, Conti B, Pastorino U, Ravagnani F, Columbano A, Skaug V, Haugen A, Dragani TA: Genome-wide single nucleotide polymorphism analysis of lung cancer risk detects the KLF6 gene. Cancer Lett; 2007 Jun 28;251(2):311-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide single nucleotide polymorphism analysis of lung cancer risk detects the KLF6 gene.
  • A genome-wide association analysis using the Affymetrix 100K SNP array was carried out in a case-control study of lung cancer.
  • DNA pooling analysis identified rs10508266 SNP, located approximately 12.5kb from the 5'-end of the KLF6 gene, as a marker showing significant association with lung cancer risk.
  • Since the SNP was in significant linkage disequilibrium with the KLF6 gene region, we analyzed an Italian population of 338 lung adenocarcinoma cases and 335 controls for the possible role of the reported functional rs3750861 SNP, located 15.6kb from the rs10508266 SNP.
  • The rs3750861 affects expression of KLF6 splicing variants in prostate cancer and we found that its rare allele is associated with reduced lung cancer risk (odds ratio, 0.5; 95% CI, 0.3-0.8).
  • A Norwegian replication series of 265 non small cell lung cancer cases, and 356 controls, however, did not confirm the association.
  • In light of the reported functional involvement of the KLF6 gene in lung cancer and in other cancer types and to the functional nature of the rs3750861 SNP, our results suggest a potential involvement of KLF6 polymorphisms in lung cancer risk, although additional studies in large series are needed to confirm our findings and to elucidate the mechanism by which the KLF6 SNPs influence lung cancer risk.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Kruppel-Like Transcription Factors / genetics. Lung Neoplasms / genetics. Polymorphism, Single Nucleotide. Proto-Oncogene Proteins / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17223258.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / KLF6 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


39. Ozten N, Horton L, Lasano S, Bosland MC: Selenomethionine and alpha-tocopherol do not inhibit prostate carcinogenesis in the testosterone plus estradiol-treated NBL rat model. Cancer Prev Res (Phila); 2010 Mar;3(3):371-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selenomethionine and alpha-tocopherol do not inhibit prostate carcinogenesis in the testosterone plus estradiol-treated NBL rat model.
  • Previous studies with selenium and/or vitamin E in prostate carcinogenesis animal models have been negative, but these models may not involve oxidative stress mechanisms.
  • In this study, we examined the potential of selenomethionine and alpha-tocopherol to modulate prostate cancer development in the testosterone plus estradiol-treated NBL rat, a model that does involve sex hormone-induced oxidative stress mechanisms and prostatic inflammation.
  • The development of prostate carcinomas was not affected by dietary treatment with either agent.
  • The high dose of selenomethionine reduced the severity of epithelial dysplasia in the lateral prostate that was not associated with inflammation, and alpha-tocopherol reduced in a dose-related fashion the incidence of marked inflammation and marked epithelial dysplasia in the lateral prostate, regardless of whether these lesions were associated with inflammation. alpha-Tocopherol significantly increased the incidence of adenocarcinomas of the mammary glands at both dietary concentrations.
  • Collectively, our findings suggest that selenomethionine and alpha-tocopherol supplementation does not prevent prostate cancer in rats fed diets with nutritionally adequate levels of selenium and vitamin E.
  • Importantly, the results of the current animal studies and those reported previously were fully predictive of the outcome of the Selenium and Vitamin E Cancer Prevention Trial.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SELENIUM METHIONINE .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. VITAMIN E .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Free Radic Biol Med. 1999 Apr;26(7-8):1034-53 [10232849.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3282-8 [9699656.001]
  • [Cites] Am J Epidemiol. 2005 Jan 15;161(2):153-60 [15632265.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):94-102 [15657339.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1170-81 [15498784.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1256-62 [15817614.001]
  • [Cites] JAMA. 2005 Jul 6;294(1):56-65 [15998891.001]
  • [Cites] Cancer Causes Control. 2005 Nov;16(9):1125-31 [16184479.001]
  • [Cites] Annu Rev Med. 2006;57:49-63 [16409136.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):245-54 [16478743.001]
  • [Cites] Am J Clin Nutr. 2007 Jan;85(1):209-17 [17209198.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1128-35 [17548674.001]
  • [Cites] Nutr Cancer. 2007;57(2):184-93 [17571952.001]
  • [Cites] Am J Epidemiol. 2007 Aug 1;166(3):280-8 [17557900.001]
  • [Cites] Vitam Horm. 2007;76:1-21 [17628169.001]
  • [Cites] Vitam Horm. 2007;76:493-518 [17628187.001]
  • [Cites] Am J Pathol. 2007 Oct;171(4):1334-41 [17717140.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):75-87 [17943452.001]
  • [Cites] Prostate. 2008 May 15;68(7):728-39 [18302197.001]
  • [Cites] Nutr Cancer. 2008;60(2):155-63 [18444146.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):1005-12 [18310093.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2008 Nov;11(6):718-26 [18827575.001]
  • [Cites] Mol Nutr Food Res. 2008 Nov;52(11):1247-60 [18727008.001]
  • [Cites] Am J Clin Nutr. 2008 Dec;88(6):1567-75 [19064517.001]
  • [Cites] JAMA. 2009 Jan 7;301(1):39-51 [19066370.001]
  • [Cites] Cancer Prev Res (Phila). 2009 May;2(5):484-95 [19401524.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3577-83 [19528373.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):893-9 [10548318.001]
  • [Cites] J Natl Cancer Inst Monogr. 2000;(27):75-93 [10963621.001]
  • [Cites] J Natl Cancer Inst Monogr. 2000;(27):95-112 [10963622.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 20;92(24):2018-23 [11121464.001]
  • [Cites] Lab Invest. 2001 May;81(5):735-47 [11351045.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 19;93(24):1872-9 [11752012.001]
  • [Cites] Carcinogenesis. 2002 Feb;23(2):329-33 [11872641.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5178-82 [12234981.001]
  • [Cites] Eur J Cancer Prev. 2002 Aug;11 Suppl 2:S18-27 [12570331.001]
  • [Cites] Prostate. 2003 Apr 1;55(1):1-8 [12640655.001]
  • [Cites] BJU Int. 2003 May;91(7):608-12 [12699469.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):866-71 [14504196.001]
  • [Cites] Eur J Cancer. 2004 Jun;40(9):1404-11 [15177500.001]
  • [Cites] Lab Invest. 1990 Mar;62(3):244-78 [2107367.001]
  • [Cites] Toxicol Appl Pharmacol. 1992 Feb;112(2):300-9 [1539166.001]
  • [Cites] Cancer Lett. 1994 Sep 15;84(2):155-62 [8076372.001]
  • [Cites] Carcinogenesis. 1995 Jun;16(6):1311-7 [7788848.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 18;90(6):440-6 [9521168.001]
  • [Cites] Br J Urol. 1998 May;81(5):730-4 [9634050.001]
  • [Cites] Carcinogenesis. 1999 Aug;20(8):1597-606 [10426813.001]
  • (PMID = 20179302.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016087; United States / NIEHS NIH HHS / ES / P30 ES000260-429017; United States / NIEHS NIH HHS / ES / ES000260-469017; United States / NIEHS NIH HHS / ES / P30 ES000260; United States / NCI NIH HHS / CA / P30 CA16087; United States / NCI NIH HHS / CA / CA016087-239016; United States / NIEHS NIH HHS / ES / P30 ES00260; United States / NIEHS NIH HHS / ES / ES000260-429017; United States / NIEHS NIH HHS / ES / P30 ES000260-469017; United States / NCI NIH HHS / CA / P30 CA016087-239016; United States / NCI NIH HHS / CA / R01 CA104334; United States / NCI NIH HHS / CA / R01 CA104334-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Antioxidants; 0 / Estrogens; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 964MRK2PEL / Selenomethionine; H4N855PNZ1 / alpha-Tocopherol
  • [Other-IDs] NLM/ NIHMS161244; NLM/ PMC2833232
  •  go-up   go-down


40. Kaneko A, Satoh Y, Tokuda Y, Fujiyama C, Udo K, Uozumi J: Effects of adipocytes on the proliferation and differentiation of prostate cancer cells in a 3-D culture model. Int J Urol; 2010 Apr;17(4):369-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of adipocytes on the proliferation and differentiation of prostate cancer cells in a 3-D culture model.
  • OBJECTIVE: To investigate how the mechanism of adipocyte-prostate cancer cell interaction affects the proliferation and differentiation of prostate cancer cells.
  • Cancer cells were co-cultured with the isolated mature adipocytes in 3-D collagen gel matrix culture.
  • The morphology and proliferative ability of the prostate cancer cells were examined.
  • CONCLUSIONS: Adipocytes could modulate the proliferation and differentiation of prostate cancer cell lines.
  • Activation of the PI3K pathway might be involved in the prostate cancer cell-adipocyte interaction.
  • [MeSH-major] Adenocarcinoma / pathology. Adipocytes / metabolism. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20409231.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / BAD protein, human; 0 / bcl-Associated Death Protein; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


41. Thompson IM, Lucia MS: Diagnosing prostate cancer: through a glass, darkly. J Urol; 2006 May;175(5):1598-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosing prostate cancer: through a glass, darkly.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Urol. 2006 Feb;175(2):505-9 [16406982.001]
  • (PMID = 16600709.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


42. Herawi M, Parwani AV, Irie J, Epstein JI: Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion. Am J Surg Pathol; 2005 Jul;29(7):874-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion.
  • The current study aimed to determine the incidence of various benign mimickers of prostatic adenocarcinoma most commonly encountered in a busy consultation practice.
  • All prostate needle biopsies from the consult service of one of the authors were prospectively evaluated over a 7-month period.
  • Crowded benign glands, insufficiently crowded or numerous to warrant a diagnosis of adenosis, was the second most common mimicker (146 of 567; 25.7%).
  • In the past, complete atrophy, adenosis, seminal vesicle, and granulomatous prostatitis were considered common mimickers of prostate cancer on prostatic needle biopsies.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Atrophy / metabolism. Atrophy / pathology. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. Referral and Consultation

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958851.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


43. Loberg RD, McGregor N, Ying C, Sargent E, Pienta KJ: In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. Neoplasia; 2007 Dec;9(12):1030-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration.
  • PURPOSE: Upregulation of Bcl-2 family members is a well-established mechanism in the development of androgen-independent prostate cancer.
  • EXPERIMENTAL DESIGN: We have established a prostate cancer model with VCaP prostate cancer cells in vivo to study the transition to androgen independence.
  • ) 5 days/week) in combination with surgical castration delayed the onset of androgen-independent prostate cancer growth in vivo.
  • CONCLUSIONS: We conclude that AT-101 in combination with surgical castration delays the onset of androgen-independent prostate cancer in vivo by disrupting the antiapoptotic activity of Bcl-2 upregulation during the transition to androgen independence.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Gossypol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):91-100 [15015581.001]
  • [Cites] Nat Med. 2004 Jan;10(1):33-9 [14702632.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Nov;81(22):7166-70 [6334305.001]
  • [Cites] Genes Dev. 1999 Aug 1;13(15):1899-911 [10444588.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7757-63 [15570010.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9209-16 [15604294.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):13-21 [15657349.001]
  • [Cites] Pancreas. 2005 Nov;31(4):317-24 [16258364.001]
  • [Cites] BJU Int. 2006 Jan;97(1):170-8 [16336351.001]
  • [Cites] Urol Oncol. 2006 Mar-Apr;24(2):161-8 [16520280.001]
  • [Cites] Neoplasia. 2006 Mar;8(3):163-72 [16611409.001]
  • [Cites] Breast Cancer Res Treat. 2001 Apr;66(3):239-48 [11510695.001]
  • [Cites] J Natl Cancer Inst. 2001 Nov 21;93(22):1687-97 [11717329.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):34-45 [11900250.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Jul;81(3):191-201 [12163131.001]
  • [Cites] Expert Opin Biol Ther. 2003 Apr;3(2):293-304 [12662143.001]
  • [Cites] N Engl J Med. 2003 Jul 24;349(4):366-81 [12878745.001]
  • [Cites] Semin Oncol. 2003 Oct;30(5 Suppl 16):133-42 [14613034.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1488-90 [15470210.001]
  • (PMID = 18084610.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA069568; United States / PHS HHS / / P01 A093900; United States / NCI NIH HHS / CA / P50 CA69568
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Mcl1 protein, mouse; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.4.22.- / Caspases; KAV15B369O / Gossypol; S7RL72610R / gossypol acetic acid
  • [Other-IDs] NLM/ PMC2134900
  • [Keywords] NOTNLM ; Apoptosis / BH3 domain / Bcl-2 / hormone refractory / orchiectomy
  •  go-up   go-down


44. Goto T, Nguyen BP, Nakano M, Ehara H, Yamamoto N, Deguchi T: Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population. Urology; 2008 Jul;72(1):167-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To identify predictive markers for biochemical failure after radical prostatectomy in patients with clinically confined prostate cancer.
  • METHODS: Immunohistochemistry of bcl-2, p53, Ki-67, and caveolin-1 was performed in samples of paraffin-embedded prostate cancer from 119 Japanese patients.
  • The clinicopathologic significance of staining with these markers was analyzed in relation to biochemical failure (prostate-specific antigen [PSA] >0.2 ng/mL).
  • [MeSH-major] Adenocarcinoma / surgery. Biomarkers, Tumor / analysis. Prostate-Specific Antigen / blood. Prostatectomy. Prostatic Neoplasms / surgery


45. Tsui BC, Rashiq S, Schopflocher D, Murtha A, Broemling S, Pillay J, Finucane BT: Epidural anesthesia and cancer recurrence rates after radical prostatectomy. Can J Anaesth; 2010 Feb;57(2):107-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidural anesthesia and cancer recurrence rates after radical prostatectomy.
  • PURPOSE: To determine the effect of adjunctive epidural local anesthetic and opioid infusion on disease recurrence following radical prostatectomy for adenocarcinoma under general anesthesia.
  • A long-term follow-up chart review was undertaken to determine clinically evident or biochemical (Prostate Specific Antigen > 0.2 ng x mL(-1)) recurrence of prostate cancer.
  • Biochemical recurrence of prostate cancer was observed in 11/49 study subjects and 17/50 control subjects.
  • There was one death from prostate cancer in each group and a total of five deaths in the study group and six deaths in the control group.
  • [MeSH-major] Adenocarcinoma / pathology. Anesthesia, Epidural / methods. Neoplasm Recurrence, Local / prevention & control. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Can J Anaesth. 2010 Feb;57(2):99-102 [20041356.001]
  • (PMID = 19911247.001).
  • [ISSN] 1496-8975
  • [Journal-full-title] Canadian journal of anaesthesia = Journal canadien d'anesthésie
  • [ISO-abbreviation] Can J Anaesth
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Anesthetics, Local
  •  go-up   go-down


46. Oka H, Chatani Y, Kohno M, Kawakita M, Ogawa O: Constitutive activation of the 41- and 43-kDa mitogen-activated protein (MAP) kinases in the progression of prostate cancer to an androgen-independent state. Int J Urol; 2005 Oct;12(10):899-905
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Constitutive activation of the 41- and 43-kDa mitogen-activated protein (MAP) kinases in the progression of prostate cancer to an androgen-independent state.
  • In this study, we examined whether constitutive activation of MAPK was related to the progression to androgen independence of prostate cancer.
  • METHODS: MAPK activation was examined by the appearance of phosphorylated forms and an in vitro kinase assay in four human (androgen-dependent and independent) prostate cancer cell lines and rat prostate cancer cell line Dunning (androgen-sensitive G line, and androgen-independent AT-3, AT-6 sublines).
  • CONCLUSIONS: The present fi ndings suggest that constitutive activation of MAPK may be associated with the acquisition of hormone independence in prostate cancer and that clonal selection after androgen removal and hormone-independent growth through the MAPK signal transduction pathway could begin at a relatively early period in the individual cells.
  • [MeSH-major] Adenocarcinoma / enzymology. Androgens / pharmacology. Biomarkers, Tumor / blood. Mitogen-Activated Protein Kinase Kinases / blood. Prostatic Neoplasms / enzymology. Testosterone / pharmacology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323984.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Androgens; 0 / Biomarkers, Tumor; 0 / Culture Media; 3XMK78S47O / Testosterone; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
  •  go-up   go-down


47. Kim TG, Hwi KK, Hung CS: Morphological and biochemical changes of andrographolide-induced cell death in human prostatic adenocarcinoma PC-3 cells. In Vivo; 2005 May-Jun;19(3):551-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological and biochemical changes of andrographolide-induced cell death in human prostatic adenocarcinoma PC-3 cells.
  • It showed selective cytotoxicity to prostate cancer PC-3 cells in vitro.
  • [MeSH-major] Adenocarcinoma / pathology. Anti-Inflammatory Agents, Non-Steroidal / toxicity. Diterpenes / toxicity. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15875775.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Diterpenes; 410105JHGR / andrographolide
  •  go-up   go-down


48. Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R, Krajewski S, Mercola D, Carpenter PM, Bowtell D, Ronai ZA: Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell; 2010 Jul 13;18(1):23-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.
  • Neuroendocrine (NE) phenotype, seen in >30% of prostate adenocarcinomas (PCa), and NE prostate tumors are implicated in aggressive prostate cancer.
  • Formation of NE prostate tumors in the TRAMP mouse model was suppressed in mice lacking the ubiquitin ligase Siah2, which regulates HIF-1alpha availability.
  • Tissue-specific expression of FoxA2 combined with Siah2-dependent HIF-1alpha availability enables a transcriptional program required for NE prostate tumor development and NE phenotype in PCa.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • [Cites] Prostate. 2007 May 1;67(6):645-52 [17342745.001]
  • [Cites] Cancer Cell. 2007 Apr;11(4):335-47 [17418410.001]
  • [Cites] J Biol Chem. 2010 Jan 22;285(4):2601-9 [19880525.001]
  • [Cites] Mol Cancer Res. 2009 Apr;7(4):443-51 [19372575.001]
  • [Cites] Prostate. 2007 Aug 1;67(11):1219-29 [17562539.001]
  • [Cites] Development. 2007 Nov;134(21):3917-28 [17913788.001]
  • [Cites] Genes Dev. 2007 Oct 15;21(20):2545-57 [17938240.001]
  • [Cites] Urol Int. 2007;79(4):287-96 [18025844.001]
  • [Cites] Neoplasia. 2007 Nov;9(11):938-50 [18030362.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11798-810 [18089810.001]
  • [Cites] Eur Urol. 2000 Sep;38(3):250-4 [10940696.001]
  • [Cites] Mol Cell Biol. 2001 Dec;21(24):8471-82 [11713282.001]
  • [Cites] Mol Cell. 2002 Feb;9(2):279-89 [11864602.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):32405-8 [12119283.001]
  • [Cites] J Biol Chem. 2002 Nov 15;277(46):44462-74 [12228243.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3101-6 [12626763.001]
  • [Cites] Am J Pathol. 2008 Jan;172(1):236-46 [18156212.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2622-7 [18268343.001]
  • [Cites] J Biol Chem. 2008 Feb 29;283(9):5939-49 [18160400.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1625-30 [18339840.001]
  • [Cites] Neurosci Lett. 2008 Mar 15;433(3):209-14 [18280659.001]
  • [Cites] Cell Stem Cell. 2008 Jul 3;3(1):33-43 [18593557.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9150-61 [14645526.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15504-9 [14668441.001]
  • [Cites] Prostate. 2004 Jul 1;60(2):91-7 [15162375.001]
  • [Cites] Cell. 2004 Jun 25;117(7):941-52 [15210114.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):12969-73 [8917528.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3325-30 [9269988.001]
  • [Cites] Prostate Suppl. 1998;8:18-22 [9690659.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1999 Jul-Aug;35(7):403-9 [10462204.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9209-16 [15604294.001]
  • [Cites] Dev Cell. 2005 Nov;9(5):617-28 [16256737.001]
  • [Cites] Ultrastruct Pathol. 2005 Sep-Oct;29(5):367-75 [16257863.001]
  • [Cites] EMBO J. 2005 Nov 16;24(22):3846-58 [16237459.001]
  • [Cites] Endocr Relat Cancer. 2006 Mar;13(1):151-67 [16601285.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7889-98 [16912162.001]
  • [Cites] Nat Cell Biol. 2007 Feb;9(2):210-7 [17220880.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16713-8 [18946040.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1606-29 [19001609.001]
  • [Cites] Cancer Res. 2008 Dec 1;68(23):9663-70 [19047143.001]
  • [Cites] J Biol Chem. 2008 Dec 26;283(52):36542-52 [18984585.001]
  • [Cites] Cell Metab. 2009 Jan 7;9(1):11-22 [19117543.001]
  • [Cites] Oncogene. 2009 Jan 15;28(2):289-96 [18850011.001]
  • [Cites] Prostate. 2009 Mar 1;69(4):401-10 [19058139.001]
  • [CommentIn] Asian J Androl. 2013 Jul;15(4):447-8 [23708461.001]
  • [CommentIn] Cancer Cell. 2010 Jul 13;18(1):3-4 [20609346.001]
  • (PMID = 20609350.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE18478
  • [Grant] United States / NCI NIH HHS / CA / P01 CA128814-01A25057; United States / NCI NIH HHS / CA / CA111515-05; United States / NCI NIH HHS / CA / R01 CA111515-06A2; United States / NCI NIH HHS / CA / U01CA114810; United States / NCI NIH HHS / CA / R01 CA111515-07; United States / NCI NIH HHS / CA / P01 CA128814; United States / NCI NIH HHS / CA / R01 CA111515-05; United States / NCI NIH HHS / CA / CA111515; United States / NCI NIH HHS / CA / CA111515-06A2; United States / NCI NIH HHS / CA / R01 CA111515; United States / NCI NIH HHS / CA / P50 CA090386; Canada / Canadian Institutes of Health Research / / ; United States / NCI NIH HHS / CA / U01 CA114810; United States / NCI NIH HHS / CA / P30 CA062203; United States / NCI NIH HHS / CA / CA128814-01A25057; United States / NCI NIH HHS / CA / P50CA090386
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Foxa2 protein, mouse; 0 / Hif1a protein, mouse; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 135845-92-0 / Hepatocyte Nuclear Factor 3-beta; EC 6.3.2.19 / Siah2 protein, mouse; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ NIHMS213554; NLM/ PMC2919332
  •  go-up   go-down


49. Kim HS, Kim GY, Lim SJ, Kim YW: Raf-1 kinase inhibitory protein expression in thyroid carcinomas. Endocr Pathol; 2010 Dec;21(4):253-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adolescent. Adult. Aged. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma, Medullary / metabolism. Carcinoma, Medullary / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Young Adult


50. Villeirs GM, Van Vaerenbergh K, Vakaet L, Bral S, Claus F, De Neve WJ, Verstraete KL, De Meerleer GO: Interobserver delineation variation using CT versus combined CT + MRI in intensity-modulated radiotherapy for prostate cancer. Strahlenther Onkol; 2005 Jul;181(7):424-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interobserver delineation variation using CT versus combined CT + MRI in intensity-modulated radiotherapy for prostate cancer.
  • PURPOSE: To quantify interobserver variation of prostate and seminal vesicle delineations using CT only versus CT + MRI in consensus reading with a radiologist.
  • MATERIAL AND METHODS: The prostate and seminal vesicles of 13 patients treated with intensity-modulated radiotherapy for prostatic adenocarcinoma were retrospectively delineated by three radiation oncologists on CT only and on CT + MRI in consensus reading with a radiologist.
  • The volumes and margin positions were calculated and intermodality and interobserver variations were assessed for the clinical target volume (CTV), seminal vesicles, prostate and three prostatic subdivisions (apical, middle and basal third).
  • RESULTS: Using CT + MRI as compared to CT alone, the mean CTV, prostate and seminal vesicle volumes significantly decreased by 6.54%, 5.21% and 10.47%, respectively.
  • The highest level of variation was found at the prostatic apex, followed by the prostatic base and seminal vesicles.
  • CONCLUSION: Addition of MRI to CT in consensus reading with a radiologist results in a moderate decrease of the CTV, but an important decrease of the interobserver delineation variation, especially at the prostatic apex.
  • [MeSH-major] Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Strahlenther Onkol. 2005 Nov;181(11):743-4; author reply 745-6 [16254712.001]
  • (PMID = 15995835.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


51. Nguyen TD, Poortmans PM, van der Hulst M, Studer G, Pigois E, Collen TD, Belkacemi Y, Beckendorf V, Miralbell R, Scandolaro L, Soete G, Villa S, Gez E, Thomas O, Krengli M, Jovenin N: The curative role of radiotherapy in adenocarcinoma of the prostate in patients under 55 years of age: a rare cancer network retrospective study. Radiother Oncol; 2005 Dec;77(3):286-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The curative role of radiotherapy in adenocarcinoma of the prostate in patients under 55 years of age: a rare cancer network retrospective study.
  • To determine whether radiation therapy could be an acceptable alternative to surgery in young patients with adenocarcinoma of the prostate, we analysed the outcome of 39 patients aged under 55 with organ confined tumours who received external radiation therapy in a curative intent.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Neoplasm Recurrence, Local / prevention & control. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16307812.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


52. Popa I, Fradet Y, Beaudry G, Hovington H, Beaudry G, Têtu B: Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol; 2007 Nov;20(11):1121-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization.
  • PCA3 is a specific marker of prostatic carcinoma.
  • Of the 48 sections, 28 contained prostatic adenocarcinoma and 20 had benign tissue located distant from the tumor.
  • The benign glands located in proximity of the cancer presented PCA3 expression in eight (29%) cases, whereas those situated distant to the tumor showed focal expression in 2 of 20 (10%) cases only.
  • High-grade prostatic intraepithelial neoplasia (HGPIN) expressed PCA3 in 25 of 26 (96%) cases.
  • The sensitivity, specificity, positive predictive value and negative predictive value for the detection of cancer were 93, 79, 71 and 95% for the radioactive detective method and 92, 80, 71 and 95% for the chromogenic detection method, respectively.
  • Our study shows that PCA3 RNA is expressed by most prostate cancers and HGPIN.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / metabolism. Autoradiography / methods. In Situ Hybridization / methods. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Humans. Male. Middle Aged. Predictive Value of Tests. Prostatic Intraepithelial Neoplasia / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17873893.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / prostate cancer antigen 3, human
  •  go-up   go-down


53. Phan TP, Syed AM, Puthawala A, Sharma A, Khan F: High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol; 2007 Jan;177(1):123-7; discussion 127
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose rate brachytherapy as a boost for the treatment of localized prostate cancer.
  • PURPOSE: We report the outcome and toxicities of high dose rate brachytherapy as a boost for localized prostate cancer.
  • MATERIALS AND METHODS: Between 1996 and 2003, 309 patients with prostate carcinoma were treated with external beam radiation therapy and high dose rate brachytherapy.
  • Group 1 of 67 patients had Gleason score 6 or less, pretreatment prostate specific antigen 10 ng/ml or less and clinical stage T2a or less.
  • Group 2 of 109 patients had Gleason score 7 or greater, pretreatment prostate specific antigen greater than 10 ng/ml and clinical stage T2b or greater.
  • On univariate analysis risk group, pretreatment prostate specific antigen and Gleason score were significant predictors of biochemical control.
  • However, on multivariate analysis only risk group and pretreatment prostate specific antigen were significant.
  • CONCLUSIONS: External beam radiation therapy and high dose rate brachytherapy for prostate cancer resulted in excellent biochemical control, cause specific survival and overall survival with minimal severe acute or late complications.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162020.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Yu N, Kozlowski JM, Park II, Chen L, Zhang Q, Xu D, Doll JA, Crawford SE, Brendler CB, Lee C: Overexpression of transforming growth factor β1 in malignant prostate cells is partly caused by a runaway of TGF-β1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-β type I receptor. Urology; 2010 Dec;76(6):1519.e8-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of transforming growth factor β1 in malignant prostate cells is partly caused by a runaway of TGF-β1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-β type I receptor.
  • OBJECTIVES: To elucidate the mechanism of transforming growth factor (TGF)-β1 overexpression in prostate cancer cells.
  • METHODS: Malignant (PC3, DU145) and benign (RWPE1, BPH1) prostate epithelial cells were used.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] EMBO J. 2007 Sep 5;26(17):3957-67 [17673906.001]
  • [Cites] EMBO Rep. 2008 Oct;9(10):990-7 [18704116.001]
  • [Cites] Int J Oncol. 2007 Feb;30(2):499-507 [17203233.001]
  • [Cites] Am J Pathol. 2006 Oct;169(4):1282-93 [17003485.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Apr;290(4):C1100-8 [16371439.001]
  • [Cites] Respir Res. 2006;7:2 [16390551.001]
  • [Cites] Cell Tissue Res. 2005 Oct;322(1):43-52 [15909166.001]
  • [Cites] Oncogene. 2000 Sep 14;19(39):4531-41 [11002426.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):111-6 [11237527.001]
  • [Cites] J Immunol. 2002 Oct 1;169(7):3485-91 [12244137.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Anal Biochem. 2004 Apr 1;327(1):45-54 [15033509.001]
  • [Cites] Mol Cell. 2004 Jul 23;15(2):170-1 [15260968.001]
  • [Cites] J Biol Chem. 1988 Jun 5;263(16):7741-6 [3259578.001]
  • [Cites] Mol Cell Biol. 1990 Apr;10(4):1492-7 [2108318.001]
  • [Cites] FEBS Lett. 1990 May 21;264(2):187-92 [2162782.001]
  • [Cites] Am J Respir Cell Mol Biol. 1993 Apr;8(4):417-24 [8476635.001]
  • [Cites] Science. 1995 Jun 30;268(5219):1902-6 [7604263.001]
  • [Cites] Ann Surg. 1995 Aug;222(2):146-54 [7639582.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1996 Dec;37(13):2778-82 [8977496.001]
  • [Cites] Br J Urol. 1998 Mar;81(3):403-5 [9523660.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6595-604 [9774674.001]
  • [Cites] Hepatology. 1999 May;29(5):1418-24 [10216124.001]
  • [Cites] Prostate. 1999 Jun 1;39(4):285-90 [10344218.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):2757-61 [18292494.001]
  • [Cites] FASEB J. 2008 Apr;22(4):954-65 [18039929.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Kidney Int. 2005 Sep;68(3):972-84 [16105028.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3557-67 [19447876.001]
  • [Cites] Exp Cell Res. 2007 Sep 10;313(15):3167-74 [17643425.001]
  • (PMID = 21030067.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090386-06A2; United States / NCI NIH HHS / CA / P50 CA090386; United States / NCI NIH HHS / CA / P50 CA090386-06A2; United States / NCI NIH HHS / CA / P50CA90386
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / PPP2R2A protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.1.3.16 / Protein Phosphatase 2
  • [Other-IDs] NLM/ NIHMS194313; NLM/ PMC2997920
  •  go-up   go-down


55. Xuan Q, Yang X, Mo L, Huang F, Pang Y, Qin M, Chen Z, He M, Wang Q, Mo ZN: Expression of the serine protease kallikrein 7 and its inhibitor antileukoprotease is decreased in prostate cancer. Arch Pathol Lab Med; 2008 Nov;132(11):1796-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the serine protease kallikrein 7 and its inhibitor antileukoprotease is decreased in prostate cancer.
  • It has been confirmed that kallikrein 7 (KLK7) is differentially expressed in ovarian and breast cancer.
  • Antileukoprotease overexpression is commonly associated with aggressive, high-risk, or metastatic cancer originating from various organs.
  • OBJECTIVE: To investigate the expression and potential role of hK7 and its inhibitor ALP in prostate cancer.
  • DESIGN: The mRNA expression of KLK7 and ALP transcript in benign prostate epithelial cells and prostate cancers was evaluated by semiquantitative reverse transcription-polymerase chain reaction.
  • We examined hK7 and ALP protein expression by immunohistochemistry in 20 normal prostate tissues, 50 benign prostatic hyperplasia tissues, and 103 prostate cancers.
  • Western blot examination showed protein expression of hK7 and ALP in benign prostate epithelial cells and prostate cancer cell lines.
  • RESULTS: Semiquantitative polymerase chain reaction examination revealed that the mRNA level of KLK7 and ALP was significantly decreased in prostate cancers compared with that in benign prostate epithelial cells (P < .001).
  • Immunohistochemical expression of hK7 was observed in prostate epithelial cells, whereas little or no staining was observed in prostate cancer.
  • Western blot analysis revealed that hK7 and ALP were decreased in malignant prostate epithelium.
  • CONCLUSIONS: Like hK7, ALP is down-regulated in prostate cancers, which begs the question of whether it remains an effective inhibitor of hK7 or whether it is discordant in time or space and is ineffective as an inhibitor of hK7.
  • The function of KLK7 and ALP in prostate cancer should be further studied.
  • [MeSH-major] Adenocarcinoma / metabolism. Kallikreins / metabolism. Prostatic Neoplasms / metabolism. Secretory Leukocyte Peptidase Inhibitor / metabolism
  • [MeSH-minor] Case-Control Studies. Cell Line, Tumor. Down-Regulation. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Male. Prostate / cytology. Prostate / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976018.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Secretory Leukocyte Peptidase Inhibitor; EC 3.4.21.- / KLK7 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


56. Leite KR, Camara-Lopes LH, Cury J, Dall'oglio MF, Sañudo A, Srougi M: Prostate cancer detection at rebiopsy after an initial benign diagnosis: results using sextant extended prostate biopsy. Clinics (Sao Paulo); 2008 Jun;63(3):339-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer detection at rebiopsy after an initial benign diagnosis: results using sextant extended prostate biopsy.
  • INTRODUCTION: Sextant prostate biopsy remains the standard technique for the detection of prostate cancer.
  • It is well known that after a diagnosis of small acinar proliferation (ASAP) or high grade prostate intraepithelial neoplasia (HGPIN), the possibility of finding cancer is approximately 40% and 30%, respectively.
  • OBJECTIVE: We aim to analyze follow-up biopsies on patients who initially received a benign diagnosis after exclusion of HGPIN and ASAP.
  • METHODS: From July 2000 to December 2003, 1177 patients were submitted to sextant extended prostate biopsy in our hospital.
  • We only considered patients who had a diagnosis of benign at the first biopsy and were subjected to rebiopsies up until May 2005 because of a maintained suspicion of cancer.
  • RESULTS: Cancer was initially detected in 524 patients (44.5%), and the diagnosis was benign in 415 (35.3%).
  • Rebiopsy was indicated for 76 of the latter patients (18.3%) because of a persistent suspicion of cancer.
  • Eight cases of adenocarcinoma (10.5%) were detected, six (75%) at the first rebiopsy.
  • CONCLUSION: Our data indicate that in extended prostate biopsy, the first biopsy detects more cancer, and the first, second, and third rebiopsies after an initial benign diagnosis succeed in finding cancer in 7.9% (6/55), 5.9% (1/15) and 20% (1/4) of patients, respectively.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Humans. Male. Middle Aged. Prostate-Specific Antigen / analysis. Prostatectomy. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2000 Apr;55(4):457-60 [10736483.001]
  • [Cites] J Urol. 2000 Jan;163(1):158-62 [10604336.001]
  • [Cites] J Urol. 2001 Nov;166(5):1679-83 [11586201.001]
  • [Cites] J Urol. 2002 Jun;167(6):2435-9 [11992052.001]
  • [Cites] Urology. 2002 Nov;60(5):836-40 [12429311.001]
  • [Cites] Urol Oncol. 2003 Mar-Apr;21(2):135-40 [12856642.001]
  • [Cites] J Urol. 2004 May;171(5):1850-4 [15076292.001]
  • [Cites] Urology. 2004 May;63(5):892-7; discussion 897-9 [15134973.001]
  • [Cites] Int J Biol Markers. 2004 Apr-Jun;19(2):89-92 [15255539.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):260-6 [15368469.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):1000-3 [7853548.001]
  • [Cites] J Urol. 2004 Nov;172(5 Pt 1):1822-4 [15540729.001]
  • [Cites] J Urol. 2005 Jan;173(1):70-2 [15592031.001]
  • [Cites] Int Braz J Urol. 2005 Mar-Apr;31(2):131-6 [15877832.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):952-7 [16831049.001]
  • [Cites] Clinics (Sao Paulo). 2006 Dec;61(6):545-50 [17187091.001]
  • [Cites] Urology. 2000 Apr;55(4):553-9 [10736500.001]
  • (PMID = 18568243.001).
  • [ISSN] 1807-5932
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC2664245
  •  go-up   go-down


57. Tarján M: Prognostic significance of focal neuroendocrine differentiation in prostate cancer: cases with autopsy-verified cause of death. Indian J Urol; 2010 Jan-Mar;26(1):41-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of focal neuroendocrine differentiation in prostate cancer: cases with autopsy-verified cause of death.
  • AIMS: This study was designed to evaluate the prognostic significance of focal chromogranin A (cgA) expression in prostate cancer in a series of cases with autopsy-verified cause of death.
  • METHODS AND RESULTS: Seventy seven autopsy-verified cases of prostate cancer were identified, 41 cases with metastatic disease and 36 with nonmetastatic disease at autopsy.
  • CONCLUSIONS: Focal NED seems to be a powerful negative prognostic parameter in prostate adenocarcinomas.
  • The outcome of the disease in prostate cancer can be accurately predicted based on focal NED of the tumor cells either alone or in combination with Gleason score.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endocrinol Invest. 2005;28(11 Suppl International):141-5 [16625864.001]
  • [Cites] Urology. 2003 Mar;61(3):589-95 [12639653.001]
  • [Cites] BJU Int. 2007 Jan;99(1):189-95 [17034504.001]
  • [Cites] Prostate. 1991;19(2):91-8 [1717965.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Hum Pathol. 1994 Jan;25(1):42-6 [7508883.001]
  • [Cites] Prostate. 1994;24(3):114-8 [7509483.001]
  • [Cites] Prostate. 1997 May 1;31(2):91-7 [9140121.001]
  • [Cites] Am J Clin Pathol. 2000 Mar;113(3):383-8 [10705819.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):234-9 [11488070.001]
  • [Cites] Cancer Lett. 2002 Dec 10;187(1-2):1-7 [12359344.001]
  • [Cites] Hum Pathol. 2005 May;36(5):562-70 [15948124.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):980-5 [16861969.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):477-86 [17186531.001]
  • [Cites] J Urol. 1997 Jul;158(1):171-4 [9186347.001]
  • [Cites] Nat Med. 1999 Mar;5(3):280-5 [10086382.001]
  • [Cites] Urology. 2001 Feb;57(2):291-5 [11182339.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):471-7 [11888088.001]
  • [Cites] Prostate. 2002 Oct 1;53(2):118-23 [12242726.001]
  • [Cites] Hum Pathol. 2006 Sep;37(9):1137-44 [16938518.001]
  • (PMID = 20535283.001).
  • [ISSN] 1998-3824
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2878436
  • [Keywords] NOTNLM ; Adenocarcinoma / neuroendocrine differentiation / prognosis / prostate
  •  go-up   go-down


58. Daugherty SE, Hayes RB, Yeager M, Andriole GL, Chatterjee N, Huang WY, Isaacs WB, Platz EA: RNASEL Arg462Gln polymorphism and prostate cancer in PLCO. Prostate; 2007 Jun 1;67(8):849-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RNASEL Arg462Gln polymorphism and prostate cancer in PLCO.
  • BACKGROUND: The Gln allele of the Arg462Gln polymorphism in RNASEL results in a threefold decrease in enzymatic activity, a reported deficiency in apoptotic response, and has been associated with prostate cancer in some high-risk family studies.
  • The relationship of this variant to sporadic prostate cancer remains uncertain.
  • METHODS: We conducted a nested case-control study of 1,317 prostate cancer cases and 1,842 controls from the screening arm of the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial.
  • Conditional logistic regression was used to evaluate the association between the RNASEL Arg462Gln polymorphism and prostate cancer.
  • RESULTS: No statistically significant association was observed between the Arg462Gln polymorphism and prostate cancer (compared to Arg/Arg, Gln/Arg: OR= 0.99 95% CI 0.84-1.16; Gln/Gln: OR= 0.95 95% CI 0.74-1.21), although slight non-significant differences in risk were observed among men with the Gln/Gln genotype by stage and grade.
  • CONCLUSIONS: These results suggest that the RNASEL Gln/Gln genotype does not play an important role in the etiology of prostate cancer in the general population.
  • [MeSH-major] Adenocarcinoma / genetics. Endoribonucleases / genetics. Prostatic Neoplasms / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17407163.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA09314; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 9007-49-2 / DNA; EC 3.1.- / Endoribonucleases; EC 3.1.26.- / 2-5A-dependent ribonuclease
  •  go-up   go-down


59. Kapoor N, Jain R, Surange S, Bhardwaj VK, Srivastava A: Prostate specific antigen ratio: for diagnosis and assessment of aggressiveness of malignancy of prostate. Indian J Pathol Microbiol; 2006 Apr;49(2):178-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate specific antigen ratio: for diagnosis and assessment of aggressiveness of malignancy of prostate.
  • The search for a perfect tumour marker, which would be able to distinguish benign from malignant enlargement of prostate accurately, is still not complete.
  • Total Prostate Specific Antigen (TPSA), a good test, has it's own inadequacies but Free Prostate Specific Antigen (FPSA) to TPSA ratio is emerging as a better adjuvant to it.
  • This prospective study was done to verify the utility of FPSA to TPSA ratio in diagnosis of malignancy of prostate and its relationship to Gleason grading (indicating the aggressiveness) of adenocarcinoma of prostate.
  • 100 patients with urinary symptoms, who were above fifty years of age and had prostatic enlargement, formed the study group.
  • Prostatic biopsy of all the cases was obtained and diagnostic histopathology and Gleason grading (in cases where adenocarcinoma was diagnosed) was done.
  • Thus making it very obvious that FPSA to TPSA ratio is an excellent adjuvant to TPSA for diagnosis of malignancy of prostate increasing the specificity and predictive value for positive test.
  • An inverse correlation (correlation coefficient = -0.95) was also found between PSA ratio and aggressiveness of prostate cancer, pointing towards its capability to predict the histological (Gleason) grade of the tumour.
  • [MeSH-major] Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Aged, 80 and over. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Indian J Pathol Microbiol. 2006 Jul;49(3):476
  • (PMID = 16933710.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


60. Bennett VS, Bailey DM: Cholangiocarcinoma presenting as a solitary epididymal metastasis: a case report and review of the literature. Diagn Pathol; 2007;2:33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Solid tumor metastasis to the epididymis is a rare occurrence and is mostly discovered incidentally at autopsy or after therapeutic orchidectomy for prostate cancer.
  • Computed tomography of the abdomen demonstrated an obstructive stricture of the extra-hepatic bile ducts, in keeping with a cholangiocarcinoma, through which a metal stent was endoscopically inserted for symptomatic relief.Subsequent right radical orchidectomy yielded a diffusely infiltrative adenocarcinoma obliterating the epididymis, extending into the rete testis, vas deferens and spermatic cord and showing widespread vascular and perineural invasion.
  • It serves to highlight the importance of performing a thorough examination of the male external genitalia both clinically, in the follow up of cancer patients, and at autopsy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 1983;9(1):56-9 [6822245.001]
  • [Cites] Jpn J Clin Oncol. 1994 Dec;24(6):340-4 [7830340.001]
  • [Cites] Br J Surg. 1997 Feb;84(2):198-9 [9052433.001]
  • [Cites] Int J Urol. 1998 Jan;5(1):106-7 [9535613.001]
  • [Cites] Histopathology. 2000 Oct;37(4):323-31 [11012739.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S131-45 [15502808.001]
  • [Cites] J Urol. 1989 Oct;142(4):1003-5 [2677407.001]
  • [Cites] Cancer. 1984 Aug 15;54(4):709-14 [6204734.001]
  • (PMID = 17760973.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2000863
  •  go-up   go-down


61. Velasco Latrás M, Carreras Coderch L, Antoñanzas Villar F, Coya Viña J, Martín Comín J, Martínez Carderón F, Nieto Martín-Bejarano J, Sáenz Cusí A, Serrano Bermúdez G, Echevarría Icaza A: [Cost-effectiveness analysis of samario-153 (Quadramet) for the treatment of patients with prostate cancer and bone metastases]. Clin Transl Oncol; 2005 Jun;7(5):198-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cost-effectiveness analysis of samario-153 (Quadramet) for the treatment of patients with prostate cancer and bone metastases].
  • [Transliterated title] Análisis coste-efectividad de samario-153 (Quadramet) en el tratamiento del dolor en pacientes con cáncer de próstata y metástasis óseas.
  • OBJECTIVE: To evaluate the cost-effectiveness of samarium [153Sm-EDTMP] (Quadramet) compared to conventional therapy in the treatment of pain in patients with prostate cancer and bone metastases.
  • CONCLUSION: Samarium-153 (Quadramet) is cost-effective in treating pain in patients with prostate cancer and bone metastases.
  • [MeSH-major] Adenocarcinoma / economics. Analgesics, Non-Narcotic / economics. Bone Neoplasms / economics. Organometallic Compounds / economics. Organophosphorus Compounds / economics. Prostatic Neoplasms / economics. Radioisotopes / economics

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. Samarium, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Q J Nucl Med. 2001 Mar;45(1):100-7 [11456368.001]
  • [Cites] JAMA. 1995 Aug 2;274(5):420-4 [7542352.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10 ):1583-91 [9389919.001]
  • [Cites] Nucl Med Commun. 1994 Jul;15(7):499-504 [7970425.001]
  • [Cites] Eur J Nucl Med. 1997 Oct;24(10):1210-4 [9323260.001]
  • [Cites] J Nucl Med. 1993 Nov;34(11):1839-44 [8229221.001]
  • [Cites] Urology. 2004 May;63(5):940-5 [15134985.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):509-24 [1705581.001]
  • [Cites] Cancer. 1982 Sep 1;50(5):893-9 [6178497.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1574-81 [9552068.001]
  • [Cites] Am J Roentgenol Radium Ther. 1950 Oct;64(4):559-75 [14771334.001]
  • [Cites] Nucl Med Commun. 2002 Apr;23(4):301-2 [11930182.001]
  • (PMID = 15960931.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] spa
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 0 / Organometallic Compounds; 0 / Organophosphorus Compounds; 0 / Radioisotopes; 42OD65L39F / Samarium; 745X144DZY / samarium Sm-153 lexidronam
  •  go-up   go-down


62. Tiwari P, Madabhushi A, Rosen M: A hierarchical unsupervised spectral clustering scheme for detection of prostate cancer from magnetic resonance spectroscopy (MRS). Med Image Comput Comput Assist Interv; 2007;10(Pt 2):278-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A hierarchical unsupervised spectral clustering scheme for detection of prostate cancer from magnetic resonance spectroscopy (MRS).
  • Magnetic Resonance Spectroscopy (MRS) along with MRI has emerged as a promising tool in diagnosis and potentially screening for prostate cancer.
  • Surprisingly little work, however, has been done in the area of automated quantitative analysis of MRS data for identifying likely cancerous areas in the prostate.
  • In this paper we present a novel approach that integrates a manifold learning scheme (spectral clustering) with an unsupervised hierarchical clustering algorithm to identify spectra corresponding to cancer on prostate MRS.
  • Ground truth location for cancer on prostate was determined from the sextant location and maximum size of cancer available from the ACRIN database, from where a total of 14 MRS studies were obtained.
  • Our scheme successfully identified MRS cancer voxels with sensitivity of 77.8%, false positive rate of 28.92%, and false negative rate of 20.88% on a total of 14 prostate MRS studies.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Magn Reson Med. 2003 Nov;50(5):944-54 [14587005.001]
  • [Cites] J Magn Reson Imaging. 2001 Feb;13(2):167-77 [11169821.001]
  • [Cites] NMR Biomed. 2006 Apr;19(2):188-97 [16411280.001]
  • [Cites] IEEE Trans Med Imaging. 2005 Dec;24(12):1611-25 [16350920.001]
  • [Cites] NMR Biomed. 2005 Feb;18(1):34-43 [15657908.001]
  • [Cites] Med Image Comput Comput Assist Interv. 2005;8(Pt 1):729-37 [16685911.001]
  • [Cites] N Engl J Med. 1991 Apr 25;324(17):1156-61 [1707140.001]
  • (PMID = 18044579.001).
  • [Journal-full-title] Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention
  • [ISO-abbreviation] Med Image Comput Comput Assist Interv
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03CA128081-01; United States / NCI NIH HHS / CA / CA127186-02; United States / NCI NIH HHS / CA / R03 CA128081-01; United States / NCI NIH HHS / CA / R21 CA127186-02; United States / NCI NIH HHS / CA / R21CA127186-01; United States / NCI NIH HHS / CA / R21 CA127186; United States / NCI NIH HHS / CA / R03 CA128081-02; United States / NCI NIH HHS / CA / CA128081-01; United States / NCI NIH HHS / CA / R21 CA127186-01; United States / NCI NIH HHS / CA / R03 CA128081; United States / NCI NIH HHS / CA / CA127186-01; United States / NCI NIH HHS / CA / CA128081-02
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS51853; NLM/ PMC2467507
  •  go-up   go-down


63. Nguewa PA, Calvo A: Use of transgenic mice as models for prostate cancer chemoprevention. Curr Mol Med; 2010 Nov;10(8):705-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of transgenic mice as models for prostate cancer chemoprevention.
  • Prostate cancer is a long latency type of tumor that usually develops in men older than 50 years of age.
  • Prostate epithelial neoplasia (PIN), the initial malignant lesion, progresses to invasive carcinoma over the course of years.
  • Because of the particular features of prostate carcinogenesis, this type of tumor may represent a paradigm for cancer prevention.
  • Several clinical trials have evaluated the effect of different compounds on prostate tumor development, including finasteride, selenium, vitamin E, and carotenes.
  • However, many novel chemopreventive agents that target different cancer-related pathways are being developed lately.
  • The transgenic adenocarcinoma of the mouse prostate (TRAMP) model has been validated as an accurate model to test a variety of preventive agents.
  • Genistein, alpha-difluoromethylornithine, toremifene, R-flurbiprofen, celecoxib, and green tea polyphenols have been shown to prevent prostate cancer development in TRAMP mice.
  • In conclusion, new chemopreventive compounds which are effective in animal models are likely to be tested soon in clinical trials, with the final goal of reducing prostate cancer incidence in men.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Prostatic Neoplasms / prevention & control
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma / prevention & control. Animals. Antineoplastic Agents / therapeutic use. Male. Mice. Mice, Transgenic. Models, Animal. Prostate / pathology. Selenium / therapeutic use. Vitamin E / therapeutic use

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20937024.001).
  • [ISSN] 1875-5666
  • [Journal-full-title] Current molecular medicine
  • [ISO-abbreviation] Curr. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents; 1406-18-4 / Vitamin E; H6241UJ22B / Selenium
  •  go-up   go-down


64. Gupta NP, Ansari MS, Dass SC: Transrectal ultrasound guided biopsy for detecting early prostate cancer: An Indian experience. Indian J Cancer; 2005 Jul-Sep;42(3):151-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transrectal ultrasound guided biopsy for detecting early prostate cancer: An Indian experience.
  • BACKGROUND: With the advent of prostate specific antigen the number of patients undergoing prostate biopsy has dramatically increased.
  • The sextant biopsy technique has been conventionally used for the diagnosis of prostate cancer.
  • Recently, concern has arisen that the original sextant method may not include an adequate sample of the prostate, hence it may result in high false negative rates.
  • We conducted a prospective study to determine whether the 5-region prostate biopsy technique significantly increases the chance of prostate cancer detection as compared to the sextant biopsy technique.
  • AIMS: To evaluate the efficacy of TRUS guided sextant and 5-region biopsy techniques in detecting carcinoma prostate in patients with PSA between 4 and 10 ng/ml and normal digital rectal examination.
  • METHODS AND MATERIAL: Between December 2001 and August 2003 one forty-two men, aged 49-82 years, who presented with LUTS, normal digital rectal examination (DRE) and PSA between 4 and 10 ng/ml underwent TRUS guided sextant prostate biopsy.
  • Serum PSA was reassessed after 3 months in patients whose biopsies were negative for cancer.
  • TRUS guided sextant biopsy revealed adenocarcinoma prostate in 34 men (24%).
  • Seven men (4.9%) had cellular atypia and 3(2.1%) had prostatic intraepithelial neoplasia (high grade).
  • Five (10.4%) patients were detected to have adenocarcinoma on repeat biopsy.
  • [MeSH-major] Biopsy / methods. Prostatic Neoplasms / ultrasonography. Ultrasonography, Interventional / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. India. Male. Middle Aged. Prospective Studies. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / ultrasonography. Rectum / ultrasonography. Time Factors


65. Minelli A, Bellezza I, Tucci A, Rambotti MG, Conte C, Culig Z: Differential involvement of reactive oxygen species and nucleoside transporters in cytotoxicity induced by two adenosine analogues in human prostate cancer cells. Prostate; 2009 Apr 1;69(5):538-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential involvement of reactive oxygen species and nucleoside transporters in cytotoxicity induced by two adenosine analogues in human prostate cancer cells.
  • BACKGROUND: Elevated levels of cellular oxidative stress represent a specific vulnerability of malignant cells and exposure to cytotoxic drugs is known to induce oxidative stress in cancer cells.
  • The effects of two adenosine analogues, 2-chloroadenosine and 2-chlorodeoxyadenosine, were investigated to assess their mechanism of action in prostate cancer cells.
  • METHODS: Androgen-independent and -sensitive (PC3 and LNCaP) prostate cancer cells and mouse primary prostate cultures were used in the study.
  • GSH and reactive oxygen species levels were determined by DTNB and DCFH-DA, respectively.
  • RESULTS: 2-Chloroadenosine marginally affected primary prostate cells viability whereas it was more potent than 2-chlorodeoxyadenosine in reducing viability and increasing apoptosis in both prostate cancer cell lines.
  • CONCLUSIONS: 2-Chloroadenosine, but not 2-chlorodeoxyadenosine is capable of inducing apoptosis in prostate cancer cells, an effect which may be explained at least partially by the capacity of the nucleoside analogue to modify ROS and GSH levels.
  • [MeSH-major] 2-Chloroadenosine / pharmacology. Antineoplastic Agents / pharmacology. Cladribine / pharmacology. Nucleoside Transport Proteins / metabolism. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Reactive Oxygen Species / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Animals. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Cells, Cultured. Disease Models, Animal. Glutathione / metabolism. Humans. Male. Mice. NF-E2-Related Factor 2 / metabolism. Purinergic P1 Receptor Agonists

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19107848.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / NF-E2-Related Factor 2; 0 / NFE2L2 protein, human; 0 / Nucleoside Transport Proteins; 0 / Purinergic P1 Receptor Agonists; 0 / Reactive Oxygen Species; 146-77-0 / 2-Chloroadenosine; 47M74X9YT5 / Cladribine; GAN16C9B8O / Glutathione
  •  go-up   go-down


66. Manenti G, Squillaci E, Carlani M, Mancino S, Di Roma M, Simonetti G: Magnetic resonance imaging of the prostate with spectroscopic imaging using a surface coil. Initial clinical experience. Radiol Med; 2006 Feb;111(1):22-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of the prostate with spectroscopic imaging using a surface coil. Initial clinical experience.
  • PURPOSE: The purpose of this study was to evaluate the diagnostic ability of proton magnetic resonance spectroscopic imaging (MRSI) in the detection and localisation of prostate cancer, prospectively compared with histopathologic findings.
  • MATERIALS AND METHODS: Magnetic resonance imaging (MRI) and MRSI were performed on 39 patients with prostate-specific antigen (PSA) levels greater than 4 ng/ml and suspicious findings at trans-rectal ultrasound (TRUS).
  • All patients underwent a TRUS ten-core biopsy within 30 days according to a subdivision of the prostate into octants.
  • At MRSI, cancer was defined as possible if the ratio of choline plus creatine to citrate exceeded mean normal peripheral zone values by two standard deviations (SD) or as definite if that ratio exceeded the normal value by three SD.
  • RESULTS: MRI and MRSI alone had sensitivity, specificity, positive and negative predictive values and diagnostic accuracy in the detection of prostate cancer equal to 85%, 75%; 53%, 89%; 65%, 88%; 77%, 74%; and 69%, 79%, respectively.
  • [MeSH-major] Adenocarcinoma / diagnosis. Magnetic Resonance Spectroscopy. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Needle. Humans. Magnetic Resonance Imaging. Male. Predictive Value of Tests. Prostate / pathology. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623302.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


67. Burgess LC, Rice E, Fischer T, Seekins JR, Burgess TP, Sticka SJ, Klatt K: Lycopene has limited effect on cell proliferation in only two of seven human cell lines (both cancerous and noncancerous) in an in vitro system with doses across the physiological range. Toxicol In Vitro; 2008 Aug;22(5):1297-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidemiological studies have shown a relationship between diets rich in tomato and/or lycopene and a reduction in cancer rates.
  • The Hep-G2, liver adenocarcinoma cell line, showed a reduction at the high doses after 24 h and the IMR-90, noncancerous lung cell line, showed a reduction at the highest dose after 72 h when compared to the solvent control.
  • The A431, skin carcinoma, DU-145, prostate carcinoma, HS-68, noncancerous skin, A549, lung carcinoma, and HS-578T, breast carcinoma, all showed no reduction in proliferation.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 1998 Sep 29;250(3):582-5 [9784387.001]
  • [Cites] Nutr Cancer. 1995;24(3):257-66 [8610045.001]
  • [Cites] J Nutr. 2004 Dec;134(12 Suppl):3486S-3492S [15570058.001]
  • [Cites] Int J Cancer. 2005 Mar 1;113(6):1010-4 [15514967.001]
  • [Cites] J Nutr. 2005 Feb;135(2):287-90 [15671228.001]
  • [Cites] Exp Biol Med (Maywood). 2005 Mar;230(3):171-9 [15734720.001]
  • [Cites] Biofactors. 2005;23(3):129-39 [16410635.001]
  • [Cites] Oncol Nurs Forum. 2006 Jan;33(1):127-37 [16470241.001]
  • [Cites] J Nutr. 2006 May;136(5):1287-93 [16614418.001]
  • [Cites] Toxicol In Vitro. 2007 Mar;21(2):217-23 [17140762.001]
  • [Cites] Biomed Pharmacother. 2007 Jul;61(6):366-9 [17448625.001]
  • [Cites] Arch Biochem Biophys. 1996 Dec 1;336(1):1-9 [8951028.001]
  • [Cites] J Nutr. 2001 May;131(5):1574-80 [11340118.001]
  • [Cites] Life Sci. 2001 Nov 2;69(24):2819-31 [11720086.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):391-8 [11880478.001]
  • [Cites] J Nutr. 2002 Mar;132(3):404-8 [11880563.001]
  • [Cites] J Agric Food Chem. 2002 Apr 10;50(8):2214-9 [11929273.001]
  • [Cites] J Nutr. 2002 Dec;132(12):3754-9 [12468619.001]
  • [Cites] J Med Food. 2002 Winter;5(4):181-7 [12639392.001]
  • [Cites] J Lipid Res. 2003 Oct;44(10):1927-39 [12867539.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(11):1768-75 [15251168.001]
  • [Cites] Arch Biochem Biophys. 2004 Oct 1;430(1):127-34 [15325920.001]
  • [Cites] Am J Health Syst Pharm. 2004 Aug 1;61(15):1562-6 [15372829.001]
  • [Cites] Int J Cancer. 2004 Nov 20;112(4):689-92 [15382052.001]
  • [Cites] J Med Food. 2004 Fall;7(3):284-9 [15383220.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1225-30 [10096552.001]
  • (PMID = 18434082.001).
  • [ISSN] 0887-2333
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016471; United States / NCRR NIH HHS / RR / RR016471-07; United States / NCRR NIH HHS / RR / P20 RR016471-07; United States / NCRR NIH HHS / RR / P20 RR016741
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 36-88-4 / Carotenoids; SB0N2N0WV6 / lycopene
  • [Other-IDs] NLM/ NIHMS57454; NLM/ PMC2494863
  •  go-up   go-down


68. Henderson JA, Espey DK, Jim MA, German RR, Shaw KM, Hoffman RM: Prostate cancer incidence among American Indian and Alaska Native men, US, 1999-2004. Cancer; 2008 Sep 1;113(5 Suppl):1203-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer incidence among American Indian and Alaska Native men, US, 1999-2004.
  • BACKGROUND: American Indian and Alaska Native (AI/AN) men experience lower incidence of prostate cancer than other race/ethnic populations in the US, but racial misclassification of AI/AN men threatens the validity of these estimates.
  • To the authors' knowledge, little is known concerning prostate-specific antigen (PSA) testing in AI/AN men.
  • METHODS: The authors linked cancer registry data with Indian Health Service enrollment records to improve race classification.
  • Analyses comparing cancer incidence rates and stage at diagnosis for AI/AN and non-Hispanic white (NHW) men for 6 geographic regions focused on counties known to have less race misclassification.
  • RESULTS: Prostate cancer incidence rates were generally lower in AI/AN than in NHW men for all regions combined (rate ratio of 0.68).
  • CONCLUSIONS: Prostate cancer incidence rates and the proportion of men with recent PSA testing were lower for AI/AN men than for NHW men.
  • Further research is needed among AI/AN men to evaluate strategies for better understanding the causes of the regional variation in prostate cancer incidence.


69. Mohamed MA, Greif PA, Diamond J, Sharaf O, Maxwell P, Montironi R, Young RA, Hamilton PW: Epigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. BJU Int; 2007 Apr;99(4):908-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.
  • OBJECTIVE: To explore the nuclear chromatin phenotype, overall epigenetic mechanisms, chromatin remodelling enzymes and their role as diagnostic biomarkers in prostate lesions, using high-resolution computerized quantitative digital image analysis (DIA).
  • MATERIALS AND METHODS: A tissue microarray (TMA) was constructed using paraffin wax-embedded prostatic tissues from 78 patients, containing 30 cores of benign prostatic hyperplasia (BPH), 10 of low-grade prostatic intraepithelial neoplasia (LGPIN), 38 of prostate adenocarcinoma, 20 of BPH tissue excised at 0.6-1 mm from LGPIN lesions, and 10 of BPH prostatic tissues obtained 0.6-1 mm from high-grade PIN (HGPIN) lesions.
  • In PIN lesions, there was a high chromatin content with DNA-hypermethylation, while in prostatic adenocarcinoma there was a lower chromatin content with DNA-hypomethylation and H3K9-hypoacetylation.
  • CONCLUSIONS: The present study confirms the ability of high-resolution computerized digital imaging of nuclear texture features to detect changes in chromatin phenotype, epigenetic events and the presence of chromatin remodelling, factors that can be used to distinguish between different prostatic pathologies, i.e.
  • BPH, LGPIN, HGPIN and prostate adenocarcinoma, and further allow the detection of MAC near PIN lesions.
  • Further studies are needed to elucidate the complex interplay between chromatin structure, its modifications and the progression of prostate cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Chromatin. Prostatic Intraepithelial Neoplasia / genetics. Prostatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378849.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromatin
  •  go-up   go-down


70. Jayram G, Katz MH, Steinberg GD: Radical cystectomy in patients previously treated for localized prostate cancer. Urology; 2010 Dec;76(6):1430-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical cystectomy in patients previously treated for localized prostate cancer.
  • OBJECTIVES: To present outcomes of a contemporary series of patients undergoing radical cystectomy (RC) for bladder cancer after previous treatment for localized cancer of the prostate (CaP).
  • METHODS: A retrospective review of more than 1000 RCs performed for bladder cancer between 1995 and 2008 identified 49 patients previously treated for localized CaP.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Neoplasms, Second Primary / surgery. Postoperative Complications / epidemiology. Prostatic Neoplasms / radiotherapy. Urinary Bladder Neoplasms / surgery


71. Olshavsky NA, Groh EM, Comstock CE, Morey LM, Wang Y, Revelo MP, Burd C, Meller J, Knudsen KE: Cyclin D3 action in androgen receptor regulation and prostate cancer. Oncogene; 2008 May 15;27(22):3111-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin D3 action in androgen receptor regulation and prostate cancer.
  • Prostate cancer (PCa) cell proliferation is dependent on activation of the androgen receptor (AR), a ligand-dependent transcription factor.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18084330.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA099996; United States / NCI NIH HHS / CA / CA116777; United States / NCI NIH HHS / CA / T32 CA117846; United States / NIEHS NIH HHS / ES / T32-ES07250; United States / NCI NIH HHS / CA / T32-CA117846
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgens; 0 / CCND3 protein, human; 0 / Cyclin D; 0 / Cyclin D3; 0 / Cyclins; 0 / Receptors, Androgen; 0 / Repressor Proteins; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


72. Emerson RE, Koch MO, Jones TD, Daggy JK, Juliar BE, Cheng L: The influence of extent of surgical margin positivity on prostate specific antigen recurrence. J Clin Pathol; 2005 Oct;58(10):1028-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of extent of surgical margin positivity on prostate specific antigen recurrence.
  • BACKGROUND: Positive surgical margins are an adverse prognostic factor in patients undergoing prostatectomy for prostate cancer.
  • RESULTS: The linear extent of margin positivity ranged from 0.01 to 68 mm (mean, 6.8; median, 3.0) and was associated with prostate specific antigen (PSA) recurrence in univariate logistic regression (p = 0.031).
  • In addition, the extent of margin positivity weakly correlated with preoperative PSA (p = 0.017) and tumour volume (p = 0.013), but not with age, prostate weight, Gleason score, pathological stage, or perineural invasion.
  • [MeSH-major] Adenocarcinoma / surgery. Prostate-Specific Antigen / blood. Prostatectomy. Prostatic Neoplasms / surgery


73. Naito A, Carcel-Trullols J, Xie CH, Evans TT, Mizumachi T, Higuchi M: Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line. Int J Cancer; 2008 Apr 1;122(7):1506-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line.
  • Although the net benefits of tamoxifen in adjuvant breast cancer therapy have been proven, the recurrence of the cancer in an aggressive and hormone independent form has been highly problematic.
  • We previously demonstrated the important role mitochondrial DNA (mtDNA) plays in hormone-independence in prostate cancer.
  • Here, the role of mtDNA in breast cancer progression was investigated.
  • We established hydroxytamoxifen (4-OHT) resistant HTRMCF by growing MCF-7, human breast adenocarcinoma cells, in the presence of 4-OHT.
  • Herein, our results substantiated the first evidence that the depletion of mtDNA induced by hormone therapy triggers a shift to acquired resistance to hormone therapy in breast cancer.
  • In addition, we showed that mtDNA depletion can be reversed, rendering the cancer cells susceptible to antiestrogen.
  • The fact that the hormone independent phenotype can be reversed should be a step toward more effective treatments for estrogen-responsive breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • [Cites] Br J Cancer. 2002 Dec 2;87(12):1354-9 [12454761.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2004 Jun;286(6):E1011-22 [14736707.001]
  • [Cites] Mol Cancer. 2002 Dec 9;1:9 [12513701.001]
  • [Cites] J Cell Biochem. 2004 Oct 1;93(2):358-73 [15368362.001]
  • [Cites] N Engl J Med. 1988 Dec 29;319(26):1681-92 [3205265.001]
  • [Cites] Science. 1989 Oct 27;246(4929):500-3 [2814477.001]
  • [Cites] Cancer Res. 1991 Aug 1;51(15):3867-73 [1855205.001]
  • [Cites] Breast Cancer Res Treat. 1999 Nov;58(2):87-97 [10674872.001]
  • [Cites] Arch Gynecol Obstet. 2000 Apr;263(4):170-7 [10834325.001]
  • [Cites] EMBO J. 2001 Apr 17;20(8):1910-20 [11296224.001]
  • [Cites] Mutat Res. 2001 May;488(2):119-33 [11344040.001]
  • [Cites] J Biochem Mol Toxicol. 2002;16(1):1-9 [11857771.001]
  • [Cites] Nucleic Acids Res. 2002 May 1;30(9):1929-34 [11972329.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3229-32 [8324732.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):527-37 [8133536.001]
  • [Cites] J Natl Cancer Inst. 1995 May 3;87(9):645-51 [7752269.001]
  • [Cites] Int J Cancer. 1995 May 16;61(4):529-34 [7759159.001]
  • [Cites] Cytogenet Cell Genet. 1995;71(1):99-103 [7606938.001]
  • [Cites] Eur J Cancer. 1996 Aug;32A(9):1464-76 [8911103.001]
  • [Cites] J Clin Invest. 1997 Apr 1;99(7):1751-8 [9120020.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3486-93 [9270017.001]
  • [Cites] Lancet. 1998 May 16;351(9114):1451-67 [9605801.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 [9747868.001]
  • [Cites] Nucleic Acids Res. 1999 Jun 1;27(11):2434-41 [10325435.001]
  • [Cites] CA Cancer J Clin. 1999 May-Jun;49(3):159-77 [10445015.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):719-24 [15647368.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):786-95 [15720805.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1655-63 [15753359.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3517-25 [15908662.001]
  • [Cites] Annu Rev Genet. 2005;39:359-407 [16285865.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62 [16288118.001]
  • [Cites] J Urol. 2006 Feb;175(2):468-72; discussion 472-3 [16406974.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1437-45 [16278679.001]
  • [Cites] J Pharmacol Exp Ther. 2007 May;321(2):526-35 [17277197.001]
  • (PMID = 17990320.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100846-04; United States / NCI NIH HHS / CA / R01 CA100846-01A1; United States / NCI NIH HHS / CA / CA100846; United States / NCI NIH HHS / CA / CA100846-06; United States / NCI NIH HHS / CA / CA100846-02; United States / NCI NIH HHS / CA / CA100846-03; United States / NCI NIH HHS / CA / R01 CA100846; United States / NCI NIH HHS / CA / R01 CA100846-03; United States / NCI NIH HHS / CA / CA100846-05; United States / NCI NIH HHS / CA / R01 CA100846-02; United States / NCI NIH HHS / CA / R01 CA100846-06; United States / NCI NIH HHS / CA / CA100846-01A1; United States / NCI NIH HHS / CA / R01 CA100846-04; United States / NCI NIH HHS / CA / R01 CA100846-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / DNA, Mitochondrial; 0 / DNA, Neoplasm; 0 / Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen; 17197F0KYM / afimoxifene; 22X328QOC4 / fulvestrant; 4TI98Z838E / Estradiol; EN464416SI / Ethidium
  • [Other-IDs] NLM/ NIHMS37213; NLM/ PMC2293290
  •  go-up   go-down


74. Zhang JQ, Huang XQ, Zhang J, Cai P, Chen W, Wang J, Zhou DQ, Zhang EQ: [CT guided radioactive seed (125)I implantation in treating multiple bone metastasis]. Zhonghua Yi Xue Za Zhi; 2008 Oct 28;88(39):2739-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 28 multiple bone metastatic tumor patients with 116 metastatic lesions totally, adenocarcinoma of lung in 6 cases, squamous cell carcinoma of lung, renal clear-cell carcinoma, and carcinoma of prostate in 4 cases each, hepatocellular carcinoma and colon carcinoma in 3 cases each, breast carcinoma in 2 cases, and malignant schwannoma and pancreatic cancer in 1 case each, 13 males and 15 females, aged 49.8, underwent CT guided radioactive seed (125)I implantation into bone metastatic lesions.
  • RESULTS: In these 28 cases, complete pain relief (CR) was observed in 16 cases, partial relief (PR) in 7 cases, and no change (NC) in 5 cases with an effective rate of 82.1%.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080445.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


75. Schostak M, Krause H, Miller K, Schrader M, Weikert S, Christoph F, Kempkensteffen C, Kollermann J: Quantitative real-time RT-PCR of CD24 mRNA in the detection of prostate cancer. BMC Urol; 2006;6:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative real-time RT-PCR of CD24 mRNA in the detection of prostate cancer.
  • BACKGROUND: Gene expression profiling has recently shown that the mRNA for CD24 is overexpressed in prostate carcinomas (Pca) compared to benign or normal prostate epithelial tissues.
  • Immunohistochemical studies have reported the usefulness of anti-CD24 for detecting prostate cancer over the full range of prostate specimens encountered in surgical pathology, e.g. needle biopsies, transurethral resection of prostate chips, or prostatectomies.
  • It is a small mucin-like cell surface protein and thus promises to become at least a standard adjunctive stain for atypical prostate biopsies.
  • We tested the usefulness of real-time RT-PCR for specific and sensitive detection of CD24 transcripts as a supplementary measure for discriminating between malignant and benign lesions in prostatic tissues.
  • METHODS: Total RNA was isolated from snap-frozen chips in 55 cases of benign prostatic hyperplasia (BPH) and from frozen sections in 59 prostatectomy cases.
  • CONCLUSION: The present study demonstrates the feasibility of quantitative CD24 RNA transcript detection in prostatic tissues even without previous laser microdissection.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, CD24 / metabolism. Prostatic Neoplasms / diagnosis. Reverse Transcriptase Polymerase Chain Reaction
  • [MeSH-minor] Area Under Curve. Humans. Immunohistochemistry. Male. Prostate-Specific Antigen / metabolism. Prostatic Hyperplasia / metabolism. RNA, Messenger / metabolism. ROC Curve. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2000 May;16(5):1049-54 [10762644.001]
  • [Cites] Am J Pathol. 1990 Oct;137(4):895-905 [1699423.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7585-93 [11606398.001]
  • [Cites] Cancer Lett. 1999 Aug 23;143(1):87-94 [10465342.001]
  • [Cites] Ann Urol (Paris). 2004 Oct;38(5):187-206 [15570704.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5264-70 [1327504.001]
  • [Cites] Acta Neuropathol. 1993;86(3):275-84 [8213086.001]
  • [Cites] Am J Clin Pathol. 1994 Mar;101(3):296-9 [7510927.001]
  • [Cites] Int J Cancer. 1995 Feb 8;60(4):562-6 [7829271.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4717-21 [7553654.001]
  • [Cites] Blood. 1997 May 1;89(9):3385-95 [9129046.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Aug;58(8):795-802 [10446804.001]
  • [Cites] Int J Oncol. 2005 Feb;26(2):329-36 [15645116.001]
  • [Cites] BJU Int. 2005 Feb;95(3):281-4 [15679778.001]
  • [Cites] J Pathol. 2005 Feb;205(3):359-76 [15532095.001]
  • [Cites] Int J Cancer. 2005 May 10;114(6):950-6 [15609297.001]
  • [Cites] Eur J Cancer. 2005 Apr;41(6):858-87 [15808955.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):379-86 [15863133.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2005 May;(216):8-19 [16019756.001]
  • [Cites] Mutat Res. 2005 Aug 25;576(1-2):66-79 [15950992.001]
  • [Cites] Bioinformatics. 2005 Oct 15;21(20):3905-11 [16131522.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1215-21 [12368195.001]
  • [Cites] Nature. 2002 Oct 10;419(6907):624-9 [12374981.001]
  • [Cites] Br J Cancer. 2003 Jan 27;88(2):231-6 [12610508.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4906-13 [14581365.001]
  • [Cites] Prostate. 2004 Feb 1;58(2):183-92 [14716744.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):813-5 [15173257.001]
  • [Cites] J Reprod Fertil. 1970 Aug;22(3):573-4 [4989232.001]
  • [Cites] J Immunol. 1986 May 15;136(10):3779-84 [2939133.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • (PMID = 16539730.001).
  • [ISSN] 1471-2490
  • [Journal-full-title] BMC urology
  • [ISO-abbreviation] BMC Urol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / RNA, Messenger; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC1435920
  •  go-up   go-down


76. Tao Y, Lefkopoulos D, Ibrahima D, Bridier A, Polizzi Mdel P, Wibault P, De Crevoisier R, Arriagada R, Bourhis J: Comparison of dose contribution to normal pelvic tissues among conventional, conformal and intensity-modulated radiotherapy techniques in prostate cancer. Acta Oncol; 2008;47(3):442-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of dose contribution to normal pelvic tissues among conventional, conformal and intensity-modulated radiotherapy techniques in prostate cancer.
  • High-energy external radiotherapy has become one of the most common treatment in localized prostate cancer.
  • We compared the difference of dose distribution, mainly at the 5-30 Gy dose level, in the irradiated pelvic volume among three modalities of radiotherapy for patients with prostate cancer: conventional, conformal and intensity-modulated radiotherapy (IMRT).
  • We selected six patients with prostate cancer treated by conformal radiotherapy at the doses of 46 Gy to PTVN (prostate and seminal vesicles), and 70 Gy to PTV-T (prostate).
  • [MeSH-major] Adenocarcinoma / radiotherapy. Pelvis / radiation effects. Prostatic Neoplasms / radiotherapy. Radiotherapy Dosage. Radiotherapy, Conformal. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Dose-Response Relationship, Radiation. Femur Head / radiation effects. Humans. Male. Prostate / radiation effects. Radiation Injuries / prevention & control. Rectum / radiation effects. Seminal Vesicles / radiation effects. Urinary Bladder / radiation effects

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17906985.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


77. Waltering KK, Wallén MJ, Tammela TL, Vessella RL, Visakorpi T: Mutation screening of the androgen receptor promoter and untranslated regions in prostate cancer. Prostate; 2006 Nov 1;66(15):1585-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation screening of the androgen receptor promoter and untranslated regions in prostate cancer.
  • BACKGROUND: Mechanisms, other than gene amplification, leading to overexpression of AR in androgen ablation-resistant prostate cancer remain unknown and could include genetic alterations in the promoter or untranslated regions (UTR) of the AR gene.
  • MATERIALS AND METHODS: DNAs from five prostate cancer cell lines, 19 LuCaP xenografts, 44 clinical tumors, and 36 non-malignant controls were used for screening mutations in the upstream regulatory region, promoter and the 5'- and 3'-UTRs of the AR gene with denaturating high performance liquid chromatography (DHPLC) and sequencing.
  • RESULTS: Ten different sequence variations were found in prostate cancer cell lines and xenografts.
  • However, none of them were recurrent or were found in clinical prostate cancer specimens or in normal controls.
  • CONCLUSIONS: Recurrent mutations in the promoter or UTRs of AR seem to be rare, and thus not likely mechanisms for the increased expression of the gene in the androgen ablation-resistant prostate cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Mutation. Promoter Regions, Genetic. Prostatic Neoplasms / genetics. Receptors, Androgen / genetics. Untranslated Regions

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16927275.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Receptors, Androgen; 0 / Untranslated Regions
  •  go-up   go-down


78. Möhring C, Bach P, Kosciesza S, Goepel M: [A primary adenocarcinoma of the seminal vesicles. Case report of a rare malignancy]. Urologe A; 2008 May;47(5):616-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A primary adenocarcinoma of the seminal vesicles. Case report of a rare malignancy].
  • [Transliterated title] Primäres Adenokarzinom der Samenblasen. Fallbericht einer seltenen onkologischen Entität.
  • They must be strictly differentiated from surrounding malignancies that may infiltrate the seminal vesicles from outside (e.g. prostate, rectum, and bladder carcinoma).
  • Early diagnosis may be difficult due to lack of specific symptoms.
  • Adenocarcinoma of seminal vesicles shows no expression of prostate-specific antigen or prostate-specific acid phosphatase, but there may be expression of carcinoembryonic antigen and cancer antigen 125.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Genital Neoplasms, Male / diagnosis. Seminal Vesicles
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Endosonography. Follow-Up Studies. Hematuria / etiology. Hemospermia / diagnosis. Humans. Lymph Node Excision. Magnetic Resonance Imaging. Male. Middle Aged. Prostatectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 1996 May;28(2):196-200 [8743830.001]
  • [Cites] J Urol. 1984 Sep;132(3):483-5 [6471181.001]
  • [Cites] J Vet Med A Physiol Pathol Clin Med. 2005 Apr;52(3):131-4 [15836444.001]
  • [Cites] Cancer. 1986 Jun 1;57(11):2202-6 [3697917.001]
  • [Cites] Urology. 2007 Apr;69(4):778.e11-3 [17445673.001]
  • [Cites] Pathol Int. 2004 Dec;54(12):924-9 [15598315.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):46-51 [10658909.001]
  • [Cites] Indian J Cancer. 1993 Jun;30(2):82-4 [8225382.001]
  • [Cites] Oncol Rep. 2005 Aug;14(2):401-8 [16012722.001]
  • [Cites] Urology. 2007 Apr;69(4):778.e1-3 [17445672.001]
  • [Cites] J Urol. 2002 Nov;168(5):1891-6 [12394673.001]
  • [Cites] Gan No Rinsho. 1984 Feb;30(2):205-14 [6708308.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1305-10 [15857840.001]
  • [Cites] Histopathology. 1999 Jun;34(6):562-3 [10383707.001]
  • (PMID = 18231770.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


79. Konijeti R, Henning S, Moro A, Sheikh A, Elashoff D, Shapiro A, Ku M, Said JW, Heber D, Cohen P, Aronson WJ: Chemoprevention of prostate cancer with lycopene in the TRAMP model. Prostate; 2010 Oct 1;70(14):1547-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention of prostate cancer with lycopene in the TRAMP model.
  • BACKGROUND: Dietary lycopene combined with other constituents from whole tomatoes was previously found to have greater chemopreventive effects against prostate cancer as compared to pure lycopene provided in a beadlet formulation.
  • We hypothesized that tomato paste would have greater chemopreventive effects in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice relative to equivalent lycopene doses provided from lycopene beadlets.
  • Prostate histopathology, prostate weight and serum levels of IGF-I and IGF binding protein-3 were evaluated.
  • RESULTS: The incidence of prostate cancer was significantly decreased in the LB group relative to the control group (60% vs. 95%, respectively, P = 0.0197) whereas the difference between the TP and control groups was not statistically significant (80% vs. 95%, P = 0.34).
  • There was no difference in prostate weights between the groups.
  • Total lycopene levels in the serum and prostate tissue were similarly elevated in the LB and TP groups relative to the control group.
  • The chemopreventive effects of lycopene from beadlets versus whole tomato products requires further testing in preclinical and clinical models of prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • [Cites] Biol Chem. 2006 Jan;387(1):103-11 [16497170.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):92-8 [16434593.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):836-43 [17213256.001]
  • [Cites] Arch Biochem Biophys. 2007 Feb 15;458(2):136-40 [17067545.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 Jun;133(6):351-9 [17219202.001]
  • [Cites] J Urol. 2007 Sep;178(3 Pt 2):S9-S13 [17644117.001]
  • [Cites] Eur J Clin Nutr. 2007 Oct;61(10):1196-200 [17299493.001]
  • [Cites] Am J Clin Nutr. 2007 Nov;86(5):1456-62 [17991659.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2193-203 [18006906.001]
  • [Cites] Growth Horm IGF Res. 2008 Feb;18(1):65-74 [17719253.001]
  • [Cites] Carcinogenesis. 2008 Apr;29(4):816-23 [18283040.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):3066-73 [18413778.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3342-9 [18451161.001]
  • [Cites] Nutr Rev. 2008 Dec;66(12):667-83 [19019036.001]
  • [Cites] J Nutr. 2000 May;130(5):1256-60 [10801927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):749-56 [11440960.001]
  • [Cites] Free Radic Biol Med. 2001 Dec 1;31(11):1341-51 [11728805.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 19;93(24):1872-9 [11752012.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):391-8 [11880478.001]
  • [Cites] J Natl Cancer Inst. 2003 Nov 5;95(21):1578-86 [14600090.001]
  • [Cites] Nutr Cancer. 2003;47(1):40-7 [14769536.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5891-6 [15313934.001]
  • [Cites] Methods Enzymol. 1994;234:16-33 [7808289.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1225-30 [10096552.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2203-9 [10232609.001]
  • [Cites] FASEB J. 2005 Feb;19(2):272-4 [15545302.001]
  • [Cites] J Nutr. 2006 May;136(5):1287-93 [16614418.001]
  • (PMID = 20687227.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5R01CA100938-05; United States / NCI NIH HHS / CA / 5P50CA092131-07; United States / NCI NIH HHS / CA / P50 CA092131; United States / NIDDK NIH HHS / DK / P30DK063491; United States / NCI NIH HHS / CA / R01 CA100938
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Vitamins; 1406-18-4 / Vitamin E; 36-88-4 / Carotenoids; 67763-96-6 / Insulin-Like Growth Factor I; SB0N2N0WV6 / lycopene
  • [Other-IDs] NLM/ NIHMS208546; NLM/ PMC2930120
  •  go-up   go-down


80. Fine SW: Variants and Unusual Patterns of Prostate Cancer. Surg Pathol Clin; 2008 Dec;1(1):77-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variants and Unusual Patterns of Prostate Cancer.
  • Beyond the typical acinar morphology observed in most prostatic adenocarcinoma, a spectrum of morphologic variants and prostate cancer subtypes exists.
  • These unusual entities may be further classified into (1) cancer morphologies arising by divergent differentiation of prostatic ductal, acinar, or basal cells and associated with unique clinical features or therapeutic approaches, and (2) histologies occurring in the context of usual prostatic adenocarcinoma that may result in diagnostic misinterpretation or difficulties in Gleason grade assignment, especially in limited samples.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 Elsevier Inc. All rights reserved.
  • (PMID = 26837903.001).
  • [ISSN] 1875-9181
  • [Journal-full-title] Surgical pathology clinics
  • [ISO-abbreviation] Surg Pathol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Ductal / Mucinous / Neuroendocrine / Prostate cancer / Pseudohyperplastic / Variant
  •  go-up   go-down


81. Lledó García E, Jara Rascón J, Subirá Rós D, Herranz Amo F, Martínez-Salamanca JI, Hernández Fernández C: [Scientific evidence on the use of high-intensity focal ultrasound (HIFU) in the treatment of prostatic carcinoma]. Actas Urol Esp; 2005 Feb;29(2):131-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Scientific evidence on the use of high-intensity focal ultrasound (HIFU) in the treatment of prostatic carcinoma].
  • [Transliterated title] Evidencia científica actual sobre la utilidad del ultrasonido de alta intensidad (HIFU) en el tratamiento del adenocarcinoma prostático.
  • OBJECTIVES: To evaluate in the literature scientific evidence on the use of High-Intensity Focal Ultrasound (HIFU) in the treatment of prostatic carcinoma (PC).
  • CONCLUSIONS: No high-quality clinical evidence can be established currently on the utility of HIFU as treatment of prostatic cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Prostatic Neoplasms / therapy. Ultrasound, High-Intensity Focused, Transrectal / economics
  • [MeSH-minor] Clinical Trials as Topic. Cost-Benefit Analysis. Evidence-Based Medicine. Humans. Male. Prostate-Specific Antigen / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15881912.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 22
  •  go-up   go-down


82. Di Staso M, Bonfili P, Gravina GL, Di Genesio Pagliuca M, Franzese P, Buonopane S, Osti MF, Valeriani M, Festuccia C, Enrici RM, Tombolini V: Late morbidity and oncological outcome after radical hypofractionated radiotherapy in men with prostate cancer. BJU Int; 2010 Nov;106(10):1458-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late morbidity and oncological outcome after radical hypofractionated radiotherapy in men with prostate cancer.
  • PATIENTS AND METHODS: In all, 162 men with hystologically confirmed prostate adenocarcinoma were included in the analysis.
  • CONCLUSIONS: In the present study, men with clinically localized prostate cancer had similar levels of morbidity irrespective of whether they received HFRT or CRT without any worsening in the early risk of BCF.
  • Thus, the present data provide some clinical evidence to justify trends already emerging toward HF regimens for treating clinically localised prostate cancer.
  • [MeSH-major] Prostatic Neoplasms / radiotherapy. Radiation Injuries / etiology. Urogenital System / radiation effects


83. Bañez LL, Terris MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Freedland SJ: Race and time from diagnosis to radical prostatectomy: does equal access mean equal timely access to the operating room?--Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev; 2009 Apr;18(4):1208-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Race and time from diagnosis to radical prostatectomy: does equal access mean equal timely access to the operating room?--Results from the SEARCH database.
  • BACKGROUND: African American men with prostate cancer are at higher risk for cancer-specific death than Caucasian men.
  • We hypothesize that in an equal-access health care system, time interval from diagnosis to treatment would not differ by race.
  • METHODS: We identified 1,532 African American and Caucasian men who underwent radical prostatectomy (RP) from 1988 to 2007 at one of four Veterans Affairs Medical Centers that comprise the Shared Equal-Access Regional Cancer Hospital (SEARCH) database with known biopsy date.
  • RESULTS: Median time interval from diagnosis to RP was 76 and 68 days for African Americans and Caucasian men, respectively (P = 0.004).
  • After controlling for demographic and clinical variables, race was not associated with the time interval between diagnosis and RP (P = 0.09).
  • CONCLUSIONS: In a cohort of men undergoing RP in an equal-access setting, there was no significant difference between racial groups with regard to time interval from diagnosis to RP.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):439-45 [14691120.001]
  • [Cites] J Urol. 2003 Sep;170(3):990-3 [12913756.001]
  • [Cites] Urology. 1995 Dec;46(6):825-30 [7502424.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3101-4 [9738581.001]
  • [Cites] Urology. 1999 Jun;53(6):1194-9 [10367851.001]
  • [Cites] J Urol. 2004 Nov;172(5 Pt 1):1835-9 [15540733.001]
  • [Cites] J Urol. 2004 Nov;172(5 Pt 1):1848-52 [15540736.001]
  • [Cites] Prostate. 2005 Feb 15;62(3):243-52 [15389726.001]
  • [Cites] Eur Urol. 2005 Jun;47(6):756-60 [15925069.001]
  • [Cites] J Urol. 2006 Apr;175(4):1298-302; discussion 1302-3 [16515984.001]
  • [Cites] J Med Genet. 2006 Jun;43(6):507-11 [16155194.001]
  • [Cites] Cancer J Sci Am. 1996 Jul-Aug;2(4):225-33 [9166537.001]
  • [Cites] J Urol. 2007 Feb;177(2):444-9 [17222606.001]
  • [Cites] Soc Sci Med. 2007 Jun;64(11):2189-200 [17399877.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2202-9 [17876838.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):900-8 [18181101.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):901-5 [10548319.001]
  • [Cites] Cancer Causes Control. 1999 Dec;10(6):503-11 [10616820.001]
  • [Cites] Urology. 2000 Dec 20;56(6):1016-20 [11113750.001]
  • [Cites] Urology. 2002 Oct;60(4):670-4 [12385931.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):120-6 [12582021.001]
  • [Cites] Lancet. 2003 Mar 8;361(9360):859-64 [12642065.001]
  • [Cites] J Gen Intern Med. 2004 Feb;19(2):146-55 [15009794.001]
  • (PMID = 19336564.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA092131-07; United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / P50CA58236; United States / NCI NIH HHS / CA / P50 CA092131; United States / NCI NIH HHS / CA / R01 CA100938-05; United States / NCI NIH HHS / CA / P50 CA92131-01A1; United States / NCI NIH HHS / CA / R01 CA100938
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS322182; NLM/ PMC3179689
  •  go-up   go-down


84. Lin S, Shen YH, Li HL, Yang XW, Chen T, Lu LH, Huang ZS, Liu RH, Xu XK, Zhang WD, Wang H: Acylated iridoids with cytotoxicity from Valeriana jatamansi. J Nat Prod; 2009 Apr;72(4):650-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All isolated compounds were tested for their cytotoxicity against lung adenocarcinoma (A549), metastatic prostate cancer (PC-3M), colon cancer (HCT-8), and hepatoma (Bel7402) cell lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Nat Prod. 2014 Nov 26;77(11):2575
  • (PMID = 19245261.001).
  • [ISSN] 1520-6025
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal; 0 / Iridoids
  •  go-up   go-down


85. Inman BA, Harel F, Audet JF, Meyer F, Douville P, Fradet Y, Lacombe L: Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. Eur Urol; 2005 May;47(5):695-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival.
  • BACKGROUND: Evidence suggests that the insulin-like growth factor (IGF) family is important in prostate cancer.
  • [MeSH-major] Adenocarcinoma / blood. Androgens / therapeutic use. Insulin-Like Growth Factor Binding Protein 2 / blood. Neoplasm Recurrence, Local / epidemiology. Prostatic Neoplasms / blood
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Biopsy. Disease-Free Survival. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prostate-Specific Antigen / blood. Prostatectomy. Quebec / epidemiology. ROC Curve. Retrospective Studies

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15826765.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Androgens; 0 / Biomarkers, Tumor; 0 / Insulin-Like Growth Factor Binding Protein 2; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


86. Izumi K, Mizokami A, Li YQ, Narimoto K, Sugimoto K, Kadono Y, Kitagawa Y, Konaka H, Koh E, Keller ET, Namiki M: Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes. Prostate; 2009 Aug 1;69(11):1222-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
  • BACKGROUND: Tranilast is a therapeutic agent used in treatment of allergic diseases, although it has been reported to show anti-tumor effects on some cancer cells.
  • To elucidate the effects of tranilast on prostate cancer, we investigated the mechanisms of its anti-tumor effect on prostate cancer.
  • METHODS: The anti-tumor effects and related mechanisms of tranilast were investigated both in vitro on prostate cancer cell lines and bone-derived stromal cells, and in vivo on severe combined immunodeficient (SCID) mice.
  • We verified its clinical effect in patients with advanced hormone refractory prostate cancer (HRPC).
  • CONCLUSIONS: These observations suggest that tranilast may be a useful therapeutic agent for treatment of HRPC via the direct inhibitory effect on cancer cells and suppression of TGF-beta1-associated osteoblastic changes in bone metastasis.
  • [MeSH-major] Adenocarcinoma / pathology. Anti-Allergic Agents / pharmacology. Cell Proliferation / drug effects. Osteoblasts / pathology. Prostatic Neoplasms / pathology. Transforming Growth Factor beta1 / metabolism. ortho-Aminobenzoates / pharmacology
  • [MeSH-minor] Aged. Aged, 80 and over. Animals. Apoptosis / drug effects. Bone Neoplasms / metabolism. Bone Neoplasms / pathology. Castration. Cell Cycle / drug effects. Cell Differentiation / drug effects. Cell Line, Tumor. Coculture Techniques. Disease Models, Animal. Dose-Response Relationship, Drug. Humans. Male. Mice. Mice, SCID. Middle Aged. Osteosarcoma / metabolism. Osteosarcoma / pathology. Prostate-Specific Antigen / blood

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434660.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA093900
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Transforming Growth Factor beta1; 0 / ortho-Aminobenzoates; EC 3.4.21.77 / Prostate-Specific Antigen; HVF50SMY6E / tranilast
  •  go-up   go-down


87. Stillie AL, Kron T, Fox C, Herschtal A, Haworth A, Thompson A, Owen R, Tai KH, Duchesne G, Foroudi F: Rectal filling at planning does not predict stability of the prostate gland during a course of radical radiotherapy if patients with large rectal filling are re-imaged. Clin Oncol (R Coll Radiol); 2009 Dec;21(10):760-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal filling at planning does not predict stability of the prostate gland during a course of radical radiotherapy if patients with large rectal filling are re-imaged.
  • AIMS: It has been suggested that large rectal filling is associated with an increased risk of prostate motion in radiotherapy.
  • The aim of the present study was to determine if there is a correlation between rectal distension on planning computed tomography and the intrafraction and interfraction stability of the prostate gland during a course of radical radiotherapy for prostate cancer if a protocol was used to rescan patients with excessive rectal diameter during planning.
  • MATERIALS AND METHODS: The computed tomography planning scans of 89 patients with adenocarcinoma of the prostate treated with conformal radiotherapy were reviewed.
  • All patients had three gold seed fiducial markers implanted into the prostate before planning computed tomography.
  • Rectal distension was assessed on planning computed tomography using outlines following European Organization for Research and Treatment of Cancer guidelines by measuring the rectal volume, the average cross-sectional area and the mean anterior-posterior diameter of the rectum.
  • Unifactor linear regression models showed no statistically significant relationship between intra- and interfraction prostate stability and rectal volume on planning computed tomography.
  • CONCLUSIONS: No statistically significant relationship between rectal distension on planning computed tomography and the intra- and interfraction stability of the prostate gland was identified if patients with a large rectal volume were rescanned for planning.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Prostatic Neoplasms / radiotherapy. Radiotherapy, Conformal / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19804961.001).
  • [ISSN] 1433-2981
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


88. Voeghtly LM, Thøgersen IB, Valnickova Z, Sanggaard KW, Chu CT, Oury TD, Enghild JJ: Potential clinical importance of the activation peptide of prostate-specific antigen. Int J Clin Exp Pathol; 2009;2(6):588-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential clinical importance of the activation peptide of prostate-specific antigen.
  • Prostate cancer is the second leading cause of cancer death in men.
  • Prostate specific antigen (PSA) is currently the best marker available for screening and monitoring disease recurrence, but its use has limitations.
  • This study investigates the biosynthesis, secretion and activation of PSA in a prostate adenocarcinoma cell line.
  • This rapid clearance likely interferes with detection of PSA in the early stages of prostate cancer.
  • We found that APLILSR is filtered from the bloodstream by the kidney, and is detectable in the urine of patients with prostate cancer, but not controls.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biochem. 1976 Jan;79(1):233-6 [939761.001]
  • [Cites] J Urol. 1998 Jan;159(1):5-12 [9400426.001]
  • [Cites] Cancer. 1992 Jul 1;70(1 Suppl):230-4 [1376193.001]
  • [Cites] Lancet. 1991 Nov 16;338(8777):1271-2 [1682665.001]
  • [Cites] J Biol Chem. 1990 Oct 15;265(29):17401-4 [1698775.001]
  • [Cites] Eur J Biochem. 1990 Dec 27;194(3):755-63 [1702714.001]
  • [Cites] Biochemistry. 1991 Feb 12;30(6):1723-30 [1704258.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 May;83(10):3166-70 [2422647.001]
  • [Cites] Biochim Biophys Acta. 1988 Nov 17;967(2):158-62 [3263884.001]
  • [Cites] Eur J Biochem. 1987 Dec 30;170(1-2):111-20 [3691515.001]
  • [Cites] J Biol Chem. 1981 Aug 10;256(15):8134-9 [6167573.001]
  • [Cites] Biochim Biophys Acta. 1982 May 27;716(2):151-7 [6178438.001]
  • [Cites] Biochem Biophys Res Commun. 1984 Sep 17;123(2):482-8 [6385967.001]
  • [Cites] Lab Invest. 1994 Dec;71(6):792-812 [7528831.001]
  • [Cites] J Biol Chem. 1995 Aug 4;270(31):18700-9 [7543108.001]
  • [Cites] Cancer. 1993 Aug 1;72(3 Suppl):1050-5 [7687518.001]
  • [Cites] Prostate Suppl. 1996;7:64-9 [8950366.001]
  • [Cites] Prostate. 1998 May;35(2):135-43 [9568677.001]
  • [Cites] JAMA. 1998 May 20;279(19):1542-7 [9605898.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6958-63 [11559576.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(2):163-8 [12806377.001]
  • [Cites] Rev Urol. 2000;2 Suppl 4:S5-9 [16986040.001]
  • [Cites] Biochemistry. 1979 Feb 20;18(4):690-3 [84683.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):841-5 [1371559.001]
  • [Cites] Hum Pathol. 1992 Mar;23(3):273-9 [1555838.001]
  • [Cites] J Urol. 1990 Dec;144(6):1523-6 [1700162.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):222-6 [1703033.001]
  • [Cites] FEBS Lett. 1987 Apr 20;214(2):317-22 [2436946.001]
  • [Cites] J Biol Chem. 1987 Jul 25;262(21):10035-8 [3611052.001]
  • [Cites] J Biol Chem. 1985 Feb 25;260(4):2432-6 [3919001.001]
  • [Cites] Urology. 2000 Apr;55(4):560-3 [10736503.001]
  • [Cites] Annu Rev Med. 2002;53:355-68 [11818479.001]
  • [Cites] Clin Chem. 2004 Jun;50(6):1017-25 [15054080.001]
  • [Cites] Pediatr Res. 1982 Aug;16(8):613-20 [6180371.001]
  • [Cites] J Urol. 1994 Nov;152(5 Pt 1):1358-68 [7523702.001]
  • [Cites] Clin Chem. 1995 Nov;41(11):1567-73 [7586544.001]
  • [Cites] Can J Oncol. 1994 Nov;4 Suppl 1:65-9 [8853493.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1195-200 [1371233.001]
  • (PMID = 19636406.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2713450
  • [Keywords] NOTNLM ; PSA / activation peptide / prostate cancer
  •  go-up   go-down


89. Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R: Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology; 2007 Mar;50(4):472-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique.
  • AIMS: To determine prostate-specific membrane antigen (PSMA) expression in normal tissues and in 3161 benign and malignant tumours and subsequently to define its sensitivity and specificity in prostatic adenocarcinoma (PaC).
  • Furthermore, its sensitivity and specificity in differentiating PaC from urothelial cancer is 65.9% and 82.9%, respectively.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Female. Humans. Immunohistochemistry. Male. Organ Specificity. Prostate / metabolism. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / metabolism. Reference Values. Sensitivity and Specificity. Tissue Array Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448023.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Surface; EC 3.4.17.21 / Glutamate Carboxypeptidase II; EC 3.4.17.21 / glutamate carboxypeptidase II, human
  •  go-up   go-down


90. Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, Alvord WG, Greenberg NM, Hurwitz AA: Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res; 2009 Aug 01;69(15):6256-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.
  • We reported previously that tumor-specific CD8(+) T cells (TcR-I) become tolerant in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
  • In this study, we show that CD4(+) TcR transgenic (TcR-II) T cells transferred into TRAMP mice became activated in lymph nodes, trafficked to the prostate, and initially functioned as T(H)1 cells.
  • Although a single cotransfer of TcR-II cells delayed TcR-I cell tolerization, repeated transfer of TcR-II cells was required to prevent TcR-I cell tolerization and significantly slowed progression of TRAMP prostate tumors.
  • These findings will assist in the design of more effective immunotherapeutic approaches for cancer.
  • [MeSH-major] Adenocarcinoma / immunology. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Dendritic Cells / immunology. Prostatic Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1994 Mar 1;56(5):755-60 [8314354.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1731-7 [8156501.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Immunity. 1995 Jun;2(6):573-85 [7796292.001]
  • [Cites] Immunol Res. 1995;14(2):119-31 [8530876.001]
  • [Cites] J Exp Med. 1996 Aug 1;184(2):747-52 [8760829.001]
  • [Cites] J Immunol. 1996 Oct 1;157(7):2764-8 [8816378.001]
  • [Cites] Nat Med. 1996 Oct;2(10):1096-103 [8837607.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1178-83 [9448305.001]
  • [Cites] Nat Med. 1998 Mar;4(3):321-7 [9500606.001]
  • [Cites] Nature. 1998 Jun 4;393(6684):478-80 [9624004.001]
  • [Cites] Nature. 1998 Jun 4;393(6684):480-3 [9624005.001]
  • [Cites] Cancer Immunol Immunother. 1999 Oct;48(7):346-52 [10501846.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1616-26 [15931392.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6 [15980149.001]
  • [Cites] Nat Rev Immunol. 2006 May;6(5):383-93 [16622476.001]
  • [Cites] J Immunol. 2007 Feb 1;178(3):1268-76 [17237372.001]
  • [Cites] Immunology. 2007 Feb;120(2):148-59 [17274112.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2203-8 [10786685.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 6;92(17):1388-402 [10974075.001]
  • [Cites] J Immunol. 2000 Dec 1;165(11):6047-55 [11086036.001]
  • [Cites] J Exp Med. 2000 Dec 4;192(11):1637-44 [11104805.001]
  • [Cites] Nature. 2003 Feb 20;421(6925):852-6 [12594515.001]
  • [Cites] Science. 2003 Apr 11;300(5617):337-9 [12690201.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2591-601 [15728465.001]
  • [Cites] Science. 2003 Apr 11;300(5617):339-42 [12690202.001]
  • [Cites] Nat Immunol. 2004 Sep;5(9):927-33 [15300249.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2985-9 [1532662.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):1043-50 [8439951.001]
  • [Cites] Biotechnol Ther. 1993;4(3-4):197-211 [7507387.001]
  • [RetractionIn] Cancer Res. 2016 Apr 15;76(8):2490 [27013202.001]
  • (PMID = 19622771.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA84296; United States / Intramural NIH HHS / / Z01 BC010563-04; United States / NCI NIH HHS / CA / U01 CA084296; United States / PHS HHS / / Z01 010954; United States / NCI NIH HHS / BC / Z01 BC010954; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400; United States / Intramural NIH HHS / / Z01 BC010653-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD40; 147205-72-9 / CD40 Ligand
  • [Other-IDs] NLM/ NIHMS123673; NLM/ PMC2732120
  •  go-up   go-down


91. Zissimopoulos A, Bantis A, Stellos K, Petrakis G, Matthaios D: Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients. J BUON; 2008 Jan-Mar;13(1):69-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients.
  • PURPOSE: To evaluate the clinical usefulness of serum procollagen I carboxyterminal propeptide (PICP) and prostate specific antigen (PSA) in relation to bone scan results in Greek patients with prostate cancer (PC).
  • The diagnosis of PC was confirmed histologically.
  • CONCLUSION: PICP could be useful for diagnosing early bone metastases of prostate adenocarcinoma and in combination with PSA and bone scan can be an additional tool in the follow-up of patients with PC.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Bone and Bones / radionuclide imaging. Peptide Fragments / blood. Procollagen / blood. Prostate-Specific Antigen / blood. Prostatic Neoplasms / pathology


92. Rozet F, Lesur G, Cathelineau X, Barret E, Smyth G, Soon S, Vallancien G: Oncological evaluation of prostate sparing cystectomy: the Montsouris long-term results. J Urol; 2008 Jun;179(6):2170-4; discussion 2174-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncological evaluation of prostate sparing cystectomy: the Montsouris long-term results.
  • PURPOSE: Prostate sparing cystectomy provides an alternative therapeutic option in highly selected patients with invasive bladder cancer who wish to avoid the significant functional side effects of traditional surgery.
  • Concern exists regarding the oncological safety of this technique especially with regard to the presence of prostatic urothelial cancer and incidental prostate adenocarcinoma.
  • MATERIALS AND METHODS: Between October 1992 and June 2004 a total of 117 patients were selected for prostate sparing cystectomy after meeting the inclusion criteria.
  • RESULTS: Nine patients underwent radical cystoprostatectomy after prostate urothelial carcinoma was diagnosed intraoperatively.
  • Of 6 patients found to have prostate adenocarcinoma in transurethral prostate resection specimens 1 was treated with high intensity focused ultrasound and 5 were followed with active surveillance, 2 of whom later died of bladder cancer.
  • CONCLUSIONS: We report oncological data on the largest prospective cohort of patients, with the longest followup, treated by prostate sparing cystectomy to date.
  • With appropriate screening the risk of a clinically significant prostate cancer appears to be low.
  • [MeSH-minor] Follow-Up Studies. Humans. Male. Middle Aged. Prostate. Time Factors. Urologic Surgical Procedures, Male / methods

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423740.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Alhopuro P, Karhu A, Winqvist R, Waltering K, Visakorpi T, Aaltonen LA: Somatic mutation analysis of MYH11 in breast and prostate cancer. BMC Cancer; 2008;8:263
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic mutation analysis of MYH11 in breast and prostate cancer.
  • We have previously shown that MYH11 mutations occur in human colorectal cancer, and may also be associated with Peutz-Jeghers syndrome.
  • Recently, MYH1 and MYH9 have been identified as candidate breast cancer genes in a systematic analysis of the breast cancer genome.
  • METHODS: The aim of this study was to investigate the role of somatic MYH11 mutations in two common tumor types; breast and prostate cancers.
  • A total of 155 breast cancer and 71 prostate cancer samples were analyzed for those regions in MYH11 (altogether 8 exons out of 42 coding exons) that harboured mutations in colorectal cancer in our previous study.
  • RESULTS: In breast cancer samples only germline alterations were observed.
  • One prostate cancer sample harbored a frameshift mutation c.5798delC, which we have previously shown to result in a protein with unregulated motor activity.
  • CONCLUSION: Little evidence for a role of somatic MYH11 mutations in the formation of breast or prostate cancers was obtained in this study.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Mutation, Missense. Myosin Heavy Chains / genetics. Prostatic Neoplasms / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Aug 31;406(6799):1013-5 [10984058.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4361-6 [11287639.001]
  • [Cites] Science. 2001 Sep 7;293(5536):1829-32 [11546872.001]
  • [Cites] Science. 1993 Aug 20;261(5124):1041-4 [8351518.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2660-4 [7780982.001]
  • [Cites] J Cell Sci. 1998 Apr;111 ( Pt 7):941-50 [9490638.001]
  • [Cites] Dev Cell. 2005 May;8(5):717-26 [15866162.001]
  • [Cites] Physiology (Bethesda). 2005 Aug;20:239-51 [16024512.001]
  • [Cites] Nat Struct Mol Biol. 2005 Sep;12(9):742-6 [16142228.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1322-9 [16642477.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5513-8 [18391202.001]
  • (PMID = 18796164.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MYH11 protein, human; EC 3.6.4.1 / Myosin Heavy Chains
  • [Other-IDs] NLM/ PMC2562392
  •  go-up   go-down


94. Madabhushi A, Feldman MD, Metaxas DN, Tomaszeweski J, Chute D: Automated detection of prostatic adenocarcinoma from high-resolution ex vivo MRI. IEEE Trans Med Imaging; 2005 Dec;24(12):1611-25
PDF icon [Fulltext service] Get downloadable